WO2013099739A1 - 吸収性物品、及びその製造方法 - Google Patents
吸収性物品、及びその製造方法 Download PDFInfo
- Publication number
- WO2013099739A1 WO2013099739A1 PCT/JP2012/082977 JP2012082977W WO2013099739A1 WO 2013099739 A1 WO2013099739 A1 WO 2013099739A1 JP 2012082977 W JP2012082977 W JP 2012082977W WO 2013099739 A1 WO2013099739 A1 WO 2013099739A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- chain hydrocarbon
- absorbent article
- acid
- hydrocarbon moiety
- blood
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
- A61F13/45—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the shape
- A61F13/47—Sanitary towels, incontinence pads or napkins
- A61F13/472—Sanitary towels, incontinence pads or napkins specially adapted for female use
- A61F13/47218—Sanitary towels, incontinence pads or napkins specially adapted for female use with a raised crotch region, e.g. hump
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
- A61F13/15577—Apparatus or processes for manufacturing
- A61F13/15699—Forming webs by bringing together several webs, e.g. by laminating or folding several webs, with or without additional treatment of the webs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
- A61F13/45—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the shape
- A61F13/47—Sanitary towels, incontinence pads or napkins
- A61F13/475—Sanitary towels, incontinence pads or napkins characterised by edge leakage prevention means
- A61F13/4751—Sanitary towels, incontinence pads or napkins characterised by edge leakage prevention means the means preventing fluid flow in a transversal direction
- A61F13/4756—Sanitary towels, incontinence pads or napkins characterised by edge leakage prevention means the means preventing fluid flow in a transversal direction the means consisting of grooves, e.g. channels, depressions or embossments, resulting in a heterogeneous surface level
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/20—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing organic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/34—Oils, fats, waxes or natural resins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B37/00—Methods or apparatus for laminating, e.g. by curing or by ultrasonic bonding
- B32B37/02—Methods or apparatus for laminating, e.g. by curing or by ultrasonic bonding characterised by a sequence of laminating steps, e.g. by adding new layers at consecutive laminating stations
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B37/00—Methods or apparatus for laminating, e.g. by curing or by ultrasonic bonding
- B32B37/10—Methods or apparatus for laminating, e.g. by curing or by ultrasonic bonding characterised by the pressing technique, e.g. using action of vacuum or fluid pressure
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B37/00—Methods or apparatus for laminating, e.g. by curing or by ultrasonic bonding
- B32B37/14—Methods or apparatus for laminating, e.g. by curing or by ultrasonic bonding characterised by the properties of the layers
- B32B37/16—Methods or apparatus for laminating, e.g. by curing or by ultrasonic bonding characterised by the properties of the layers with all layers existing as coherent layers before laminating
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B2307/00—Properties of the layers or laminate
- B32B2307/70—Other properties
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B2307/00—Properties of the layers or laminate
- B32B2307/70—Other properties
- B32B2307/726—Permeability to liquids, absorption
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B2535/00—Medical equipment, e.g. bandage, prostheses, catheter
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T156/00—Adhesive bonding and miscellaneous chemical manufacture
- Y10T156/10—Methods of surface bonding and/or assembly therefor
Definitions
- the present invention relates to an absorbent article and a method for producing the same.
- An absorbent article for example, a sanitary napkin, is known in which a protrusion having cushioning properties is provided on the skin contact surface side of the top sheet for the purpose of fitting to the wearer's body.
- a protrusion having cushioning properties is provided on the skin contact surface side of the top sheet for the purpose of fitting to the wearer's body.
- Patent Document 1 discloses an absorbent article that is intended to provide an absorbent article that has a good cushioning property even when the protruding portion is under a low load, is excellent in fit and wearing feeling, and is less likely to leak. Is described.
- the absorbent article described in Patent Document 1 has the following configuration: an absorbent article that includes a top sheet, a back sheet, and an absorbent layer interposed between the two, and is formed substantially vertically.
- the protrusion being disposed in the upper cushion layer close to the top sheet, And a lower cushion layer positioned below the upper cushion layer, a lower absorbent layer is disposed on the non-skin contact surface side of the lower cushion layer, and the upper cushion layer is thicker than the lower cushion layer Absorbent article that is easily deformed against pressure in the direction.
- Patent Document 2 has an absorptive property that has excellent cushioning properties, has a protruding portion that flexibly follows and deforms the movement of the wearer's skin and exhibits good fit, has low liquid spread, and does not easily generate wetback.
- An absorbent article intended to provide an article is described.
- the absorbent article described in Patent Document 2 has the following configuration: an absorbent article having an absorbent layer between a top sheet and a back sheet, wherein the absorbent layer includes a lower absorbent layer and the lower absorbent.
- An upper absorbent layer that is located on the surface sheet side of the layer and is smaller than the lower absorbent layer, and a cushion layer disposed between the lower absorbent layer and the upper absorbent layer, at the center in the width direction of the absorbent article
- the surface sheet, the upper absorbent layer, and the cushion layer form a protruding portion that protrudes toward the surface sheet, and the cushion layer is made of a fiber assembly mainly composed of hydrophilic synthetic fibers.
- the density ⁇ U of the upper absorbent layer, the density ⁇ C of the cushion layer, and the density ⁇ D of the lower absorbent layer satisfy the relationship of ⁇ C ⁇ U ⁇ D under no pressure, and the density ⁇ UP of the upper absorbent layer under pressure.
- Cushion Density RoDP density RoCP and lower absorbent layer of the layers the absorbent article satisfies the relationship ⁇ UP ⁇ ⁇ CP ⁇ ⁇ DP and ⁇ UP ⁇ DP.
- the present disclosure fits the wearer's excretion opening, particularly the labia, both at the time of dry before absorbing menstrual blood and at the time of wet after absorbing menstrual blood, and hardly leaks.
- a liquid-permeable top sheet, a liquid-impermeable back sheet, the liquid-permeable top sheet, and a liquid-impermeable back sheet An absorbent article including an absorbent body between, wherein the absorbent article has a middle-high part protruding in the thickness direction of the absorbent article in the excretory opening contact region, and the middle-high part is the top Including a part of the seat and a cushion part disposed between the top sheet and the absorber, the middle and high part has a central part and an outer peripheral part surrounding the central part, and the outer peripheral part It has been found that the above-mentioned problem can be solved by an absorbent article characterized in that the density of the cushion part is higher than the density of the cushion part in the central part.
- the absorbent article of the present disclosure fits into the wearer's excretory opening, particularly the labia, both when dry before absorbing menstrual blood and when wet after absorbing menstrual blood, causing leakage. It is hard to let you.
- FIG. 1 is a perspective view of an absorbent article according to one of the embodiments of the present disclosure.
- FIG. 2 is a front view of the absorbent article 1 shown in FIG.
- FIG. 3 is a rear view of the absorbent article 1 shown in FIG.
- FIG. 4 is an end view of the absorbent article 1 shown in FIG. 1 at the XX end face of FIG. 5 is an end view of the absorbent article 1 shown in FIG. 1 at the YY end face of FIG.
- Drawing 6 is a figure showing an example of a shape of a cushion part before being built in an absorptive article.
- FIG. 7 is an electron micrograph of the skin contact surface of the top sheet in a sanitary napkin where the top sheet contains tri-C2L oil fatty acid glycerides.
- FIG. 8 is a photomicrograph of menstrual blood with or without a blood modifying agent.
- FIG. 9 is a diagram for explaining a method of measuring the surface tension.
- FIG. 1 is a perspective view of an absorbent article according to one of the embodiments of the present disclosure.
- the absorbent article 1 shown in FIG. 1 is a sanitary napkin.
- the right back corresponds to the front of the wearer
- the left front corresponds to the rear of the wearer, but the absorbent article 1 shown in FIG. Generally, it has a symmetrical shape in the front-rear direction and the left-right symmetry.
- the absorbent article 1 shown in FIG. 1 includes a liquid-permeable top sheet 5, a liquid-impermeable back sheet (not shown), a liquid-permeable top sheet 5 and a liquid-impermeable back sheet. Including an intermediate absorber (not shown).
- FIG. 1 also shows the pressing part 4 and the peeling part 6 fixed to the back sheet.
- the absorbent article 1 shown in FIG. 1 has a middle-high part 2 that protrudes in the thickness direction of the absorbent article 1 in the excretory opening contact area.
- the top sheet 5 has a plurality of ridge groove structures extending in the longitudinal direction on the skin contact surface.
- the boundary is indicated by a solid line.
- a wide region surrounded by two solid lines means a buttock, and a narrow region surrounded by two solid lines means a groove
- a plurality of flanges and a plurality of grooves are alternately arranged in the width direction of the absorbent article 1.
- a perimeter 3 that surrounds the mid-high section 2.
- the direction perpendicular to the longitudinal direction of the absorbent article may be simply referred to as the “width direction”.
- the “middle / high portion” means a portion including a top sheet and a cushion portion, and generally has a thickness toward the outer peripheral portion from the point of having the maximum thickness of the absorbent article. Becomes thinner.
- the “central portion” means a portion including a point having the thickest thickness in the middle and high portions.
- the said thickness means the thickness from the clothing contact surface of a back seat
- the “central portion” regarding the middle-high portion is preferably 0 to about 50%, more preferably 0 to about 40%, and even more preferably the distance from the thickest point to the outer edge of the middle-high portion. It means an area of 0 to about 30%.
- FIG. 2 is a front view of the absorbent article 1 shown in FIG. 1 and is a view observed from the skin contact surface side of the top sheet 5.
- the absorbent article 1 shown in FIG. 2 includes a liquid-permeable top sheet 5, a liquid-impermeable back sheet (not shown), a liquid-permeable top sheet 5 and a liquid-impermeable back sheet. In between, the absorber 8 is included.
- the absorbent article 1 shown in FIG. 2 also has a middle-high part 2 that protrudes in the thickness direction of the absorbent article 1 in the excretory opening, particularly in the contact area of the small labia.
- the middle-high part 2 includes a part of the top sheet 5 and a cushion part 7 disposed between the top sheet 5 and the absorbent body 8.
- FIG. 2 also shows a peripheral part 3 surrounding the middle and high part 2, a pressing part 4, and a peeling part 6 fixed to the back sheet.
- FIG. 3 is a rear view of the absorbent article 1 shown in FIG. 1 and is a view observed from the clothing contact surface side of the back sheet 9.
- the upper side corresponds to the front of the wearer and the lower side corresponds to the rear of the wearer.
- the fixing part 10 is applied to the clothing contact surface of the liquid-impermeable back sheet 9, and the peeling part 6 is fixed to the fixing part 10.
- a wearer can peel the peeling part 6 at the time of use, can fix the fixing
- FIG. 4 is an end view of the absorbent article 1 shown in FIG. 1 at the XX end face of FIG.
- the right side corresponds to the front of the wearer and the left side corresponds to the rear of the wearer.
- a liquid-impermeable back sheet 9 an absorbent body 8 and a liquid-permeable top sheet 5 are laminated in order from the bottom, and in the excretory opening contact area, the cushion portion 7 is disposed between the absorbent body 8 and the liquid-permeable top sheet 5.
- the middle-high part 2 includes a part of the top sheet 5 and the cushion part 7, and the absorbent article 1 is disposed near the outer edge of the cushion part 7, more specifically, outside the cushion part. And it has the pressing part 4 formed by pressing the absorber 8.
- the liquid-permeable top sheet 5 has a plurality of groove structures on the skin contact surface.
- the density of the cushion part 7 in the outer peripheral part 12 is higher than the density of the cushion part 7 in the central part 11.
- FIG. 5 is an end view of the absorbent article 1 shown in FIG. 1 at the YY end face of FIG.
- the absorbent article 1 shown in FIG. 5 has the pressing part 4 formed by pressing the top sheet 5 and the absorber 8 in the vicinity of the outer edge of the cushion part 7, more specifically, outside the cushion part.
- the absorbent article 1 has a plurality of groove structures on the skin contact surface.
- the density of the cushion portion 7 in the outer peripheral portion 12 is higher than the density of the cushion portion 7 in the central portion 11.
- FIG. 5 shows the elastic member 13.
- the material of the cushion part is not particularly limited, and examples of the material include a fiber-containing material and a non-fiber-containing material.
- the fiber-containing material include those containing natural fibers, chemical fibers, or both, and those in which intersections of a plurality of fibers are heat-sealed are preferable. Even after the menstrual blood is absorbed, the cushion portion, and thus the middle-high portion can be excellent in shape stability by heat-sealing the intersections of the fibers.
- the fiber-containing material preferably contains about 50 to about 100% by mass, and more preferably about 70 to about 100% by mass of thermoplastic chemical fiber for heat-sealing the fibers.
- thermoplastic chemical fibers examples include polyethylene (PE), polypropylene (PP), polyethylene terephthalate (PET), PE and PP graft polymers
- thermoplastic chemical fibers include single fibers and composites.
- the fibers include core-sheath fibers, heat-shrinkable fibers, and heat-extensible fibers.
- a hydrophilic agent, a water repellent and the like can be kneaded or coated on the thermoplastic chemical fiber.
- the said thermoplastic chemical fiber can be hydrophilized by performing a corona treatment, a plasma processing, etc. to the said thermoplastic chemical fiber.
- inorganic fillers such as a titanium oxide, barium sulfate, a calcium carbonate
- the fiber which comprises a cushion part is a core sheath type fiber
- the said inorganic filler can be included in a core and / or a sheath.
- the cushion part is a fiber-containing material
- the fiber constituting the fiber-containing material is preferably a composite fiber rather than a single fiber in consideration of compression recovery, and is a core-sheath fiber including polyethylene in the sheath part. More preferably.
- the composite fiber examples include a core-sheath type in which the melting point of the core component is higher than the melting point of the sheath component, an eccentric type of the core-sheath, and a side-by-side type fiber having different melting points of the two components.
- the cushion part is a fiber-containing material
- the cushion part is a hollow fiber, a flat fiber, an irregular fiber such as a Y-shape, a C-shape, a three-dimensional crimp fiber such as a latent crimp, an actual crimp, And split fibers that are split by a physical load such as water flow, heat, embossing, and the like.
- the fibers constituting the cushion part may have a fineness of about 1.1 to about 8.8 dtex in consideration of ease of menstrual blood and the like, and touch. preferable.
- the natural fiber examples include cellulose such as pulverized pulp and cotton, regenerated cellulose such as rayon and fibril rayon, semi-synthetic cellulose such as acetate and triacetate, and the like, considering low cost and ease of molding. Pulverized pulp is preferred.
- the cushion part contains cellulose, leakage can be suppressed when it is difficult to apply body pressure to the mid-high part such as a sleeping posture. This is because when the cushion portion is formed of 100% thermoplastic chemical fiber, menstrual blood flows on the outermost surface of the top sheet, and leakage may occur.
- the cushion part is a fiber-containing material
- the cushion part is formed by web forming, for example, dry type (card method, spun bond method, melt blown method, air laid method, TOW, etc.), wet type, or a combination thereof. Can be formed.
- the method for bonding the cushion portion include thermal bonding, needle punching, chemical bonding, and hydroentanglement method.
- non-fiber-containing material examples include continuous foams such as elastomer and foamed polyethylene.
- examples of the elastomer include polyester-based, urethane-based, olefin-based, styrene-based, and polyamide-based thermoplastic elastomers, low-density polyethylene using a metallocene catalyst, ethylene- ⁇ -olefin copolymer, combinations thereof, and the like.
- examples of the polyester elastomer include those containing aromatic polyester as a hard segment and amorphous polyether, aliphatic polyester or the like as a soft segment.
- the continuous foam means an open-type foam in which foam cells are open.
- the closed-pore foam in which the foamed cells are not open is inferior in liquid permeability because menstrual blood hardly passes through the inside of the cushion portion.
- Examples of the urethane elastomer include polyurethanes made of polyester, low molecular glycol, methylene bisphenyl isocyanate, etc. as thermoplastic elastomers.
- Examples of the olefin elastomer include a random copolymer of ethylene and ⁇ -olefin, a random copolymer of ethylene, ⁇ -olefin and diene, and the like.
- As said styrene-type elastomer block copolymers, such as SEBS, SIS, SEPS, SBS, are mentioned, for example.
- Examples of the polyamide-based elastomer include those containing nylon as a hard segment and polyester or polyol as a soft segment.
- the non-fiber-containing material can contain high-density polyethylene, low-density polyethylene, linear low-density polyethylene, etc. for molding stability.
- the non-fiber-containing material may contain an anti-blocking agent, an ultraviolet absorber, a thickening branching agent, a matting agent, a colorant, and other various improving agents.
- a hydrophilic agent, a water repellent, or the like can be kneaded or coated on the non-fiber-containing material.
- the said non-fiber containing material can be hydrophilized by performing a corona treatment, a plasma treatment, etc. to the said non-fiber containing material.
- the disclosure according to claim 1 of the present application is the effect of the present disclosure, that is, when the dry portion before absorbing menstrual blood and when wet after absorbing menstrual blood,
- the reason for having an effect of fitting to the small labia and not causing leakage is considered as follows.
- the shape of the labia of adult women is not constant and varies from person to person, but it is difficult to deform when the body is moved, especially than the labia.
- the large labia differs greatly in the degree of deformation when the body is moved depending on the body shape of the woman. When the body is moved, the large labia is very easily deformed when the body is moved.
- the middle and high portions are present in the excretory opening contact area, and the density of the cushion portion constituting the middle and high portions is different between the outer peripheral portion and the central portion of the middle and high portions, and the cushion portion in the outer peripheral portion is The density is higher than the density of the cushion part in the central part. Therefore, the relatively low-density cushion part in the middle part of the middle-high part has low rigidity, and when it comes into contact with the small labia, it deforms along the shape of the small labia and can bury the small labia.
- the relatively high-density cushion part in the outer peripheral part of the middle and high parts has high rigidity, and keeps contacting the boundary between the small labia and the large labia or the large labia when dry before absorbing menstrual blood. be able to.
- the relatively high-density cushion part in the outer peripheral part of the middle-high part has high compression recovery, so that it keeps in contact with the excretory opening having a complicated shape even when wet after absorbing menstrual blood. Can do.
- the “excretion opening contact area” means an area in contact with the wearer's excretion opening, and the above “excretion opening” mainly means the labia minora, but the outer peripheral part of the middle and high parts However, it does not prevent you from touching the labia.
- the middle part of the middle and high parts since the middle part of the middle and high parts is easily compressed, it deforms into a concave shape along the shape of the wearer's small labia while wearing it, the small labia is buried, the top sheet is brought into close contact with the vaginal opening, and the top sheet The menstrual blood can be prevented from spreading excessively.
- the top sheet can be in close contact with the vaginal opening, when wearing, the distance between the vaginal opening and the absorber is close, and the cushion part is mainly composed of thermoplastic chemical fibers.
- the menstrual blood can pass through the top sheet and the cushion portion without being diffused in the plane direction, and can be quickly transferred to the absorber. Once the passage of menstrual blood is made, the area is hydrophilized. Therefore, menstrual blood passes through the top sheet and the cushion portion and absorbs quickly after absorption of menstrual blood for the second and subsequent times. Can be migrated.
- the volume of the cushion part temporarily decreases, and even when a large amount of menstrual blood stays in the cushion part where the volume is reduced, Since the bulk of the cushion portion is quickly recovered around the outer peripheral portion of the portion, menstrual blood can be rapidly transferred to the absorber.
- the absorbent article of the present disclosure is characterized in that the density of the cushion portion in the outer peripheral portion of the middle-high portion is higher than the density of the cushion portion in the middle portion of the middle-high portion, but the absorption according to one embodiment of the present disclosure
- the said feature is achieved by having the pressing part formed by pressing at least a top sheet and an absorber near the outer edge of a cushion part, for example.
- an absorbent article (i) squeezing the outer edge of the cushion part, and then laminating a liquid-impermeable back sheet, an absorbent body, a cushion part, and a top sheet in order.
- the top sheet By having at least a compressed portion formed by pressing the top sheet and the absorbent body in the vicinity of the outer edge of the cushion section, the top sheet is difficult to peel from the absorbent body when wet after absorbing menstrual blood, for example. Moreover, the high density of the cushion part in the outer peripheral part of a middle-high part can be hold
- the vicinity of the outer edge” regarding the cushion part is a concept including not only the outer edge of the cushion part but also the inner side of the outer edge of the cushion part and the outer side of the outer edge of the cushion part.
- “near” is preferably a range of ⁇ 15%, more preferably ⁇ 10% of the distance from the center of the cushion portion to the outer edge of the cushion portion in the planar direction of the absorbent article, and more preferably ⁇ 10%. Means ⁇ 5% range.
- center regarding a cushion part means the center of the longitudinal direction and width direction of an absorbent article.
- FIGS. 1 to 5 there is a squeezed portion formed by continuously squeezing the top sheet and the absorbent body on the outside of the cushion portion, but the absorbency in another embodiment of the present disclosure
- the absorbent article there can be a squeezed portion formed by intermittently squeezing the top sheet and the absorbent body outside the cushion portion.
- the pressing part formed by pressing only a cushion part continuously or intermittently can exist in the edge of a cushion part.
- the shape of the cushion part before being incorporated into the absorbent article is such that after the cushion part is incorporated, the density of the cushion part at the outer peripheral part of the middle-high part is higher than the density of the cushion part at the center part of the middle-high part.
- the projection in the thickness direction of the absorbent article has a shape similar to the labia, for example, a substantially circular shape, a substantially elliptical shape, a substantially rounded rectangular shape, It can be a figure surrounded by two arcs.
- the cushion portion may have a constant thickness in the thickness direction of the absorbent article, the thickness may increase from the center toward the outer edge, or the thickness may increase from the center toward the outer edge. Can be thinned.
- the thickness of the cushion part becomes thinner from the center toward the outer edge, when the absorber and the top sheet are squeezed, the density of the cushion part in the outer peripheral part of the middle and high parts is Since it may be difficult to increase the density of the cushion portion, it is preferable that the cushion portion has a constant thickness or a thickness that increases from the center toward the outer edge.
- the basis weight of the cushion portion may vary depending on the location.
- FIG. 6 is a diagram showing an example of the shape of the cushion portion before being incorporated into the absorbent article.
- FIG. 6A is a cushion part before being incorporated into the absorbent article, in which the projection in the thickness direction of the absorbent article is substantially elliptical and the thickness is constant
- FIG. FIG. 6 (c) is a cushion before being incorporated into the absorbent article, in which the projection in the thickness direction of the absorbent article is a figure surrounded by two arcs and the thickness is constant.
- the density of the cushion portion at the middle portion of the mid-high portion is preferably about 0.001 to 0.1 g / cm 3 , more preferably about 0.005 to about 0.08 g / cm 3 , and still more preferably about 0.01. To about 0.05 g / cm 3 .
- the density is less than about 0.001 g / cm 3 , compression recovery tends to be insufficient when wet after absorbing menstrual blood, and the density is greater than about 0.1 g / cm 3. Then, it tends to deform along the wearer's small labia and make it difficult to fit the labia.
- the density of the cushion part in the center part and outer peripheral part of a middle-high part can be measured as follows. (1) Using a two-dimensional laser displacement meter, measure the thickness t (cm) of the cushion portion at the position to be measured. Examples of the two-dimensional laser displacement meter include a high-precision two-dimensional laser displacement meter LJ-G series (model: LJ-G030) manufactured by Keyence Corporation.
- the thickness of the cushion part at the position to be measured is determined from the thickness of the absorbent article at the position to be measured by the thickness of the absorbent article in the region where the cushion part does not exist, i.e., the peripheral part surrounding the middle and high parts. It can be calculated by subtracting.
- the ratio of the density at different positions of the cushion portion can be simply compared by their thickness. That is, when the basis weight of the cushion portion is constant, it means that the thinner the cushion portion, the higher the density of the cushion portion.
- the density of the cushion portion in the outer peripheral portion of the middle-high portion is higher than the density of the cushion portion in the middle portion of the middle-high portion, preferably about the density of the cushion portion in the middle portion of the middle-high portion. 1.1 to about 5.0 times higher, more preferably about 1.2 to about 4.0 times higher than the density of the cushion portion in the middle high section, and more preferably in the middle middle section About 1.5 to about 3.0 times higher than the density of the cushion part.
- the ratio is less than about 1.1 times, when wet, there is a tendency that the compression recovery property of the cushion portion at the outer periphery of the middle and high portions is insufficient, and when the ratio is more than about 5 times, The cushion part at the outer peripheral part of the part has high rigidity, and the wearer tends to feel a foreign object.
- the maximum thickness of the cushion portion is preferably about 3 to about 30 mm, more preferably about 4 to about 20 mm, and further about 5 to about 10 mm. preferable.
- the maximum thickness of the cushion part is within the above range, it can fit into the excretion opening of the wearer, in particular, the labia, at the time of wearing, and can hardly cause leakage.
- the “maximum thickness” regarding the cushion part and the middle-high part means the thickness of the thickest part of the cushion part and the middle-high part, respectively.
- the cushion portion preferably has a longitudinal length of the absorbent article, preferably about 10 to about 100 mm, of about 30 to about 300 mm, more preferably about 40 to about 250 mm, and even more preferably about 50 to about 100 mm. More preferably from about 20 to about 70 mm, and even more preferably from about 25 to about 50 mm, in the width direction of the absorbent article.
- the middle and high part will not fit into the wearer's excretion opening, especially the labia, and leakage will easily occur, and if the size of the cushion part is larger than the above range, it will be worn Sometimes it is easy to feel a sense of incongruity, and a gap with the labia tends to occur, and leakage tends to occur.
- longitudinal direction means the longitudinal direction of the absorbent article
- width direction means the width direction of the absorbent article
- thickness means the thickness direction of the absorbent article
- the cushion portion is preferably about 50 to about 1,000 g / m 2 , preferably about 100 to 500 g / m 2 , and more preferably about 150 to about 300 g / m 2 .
- Have quantity By having a basis weight within the above range, even when wet after absorbing menstrual blood, the middle and high parts do not collapse, the middle and high parts fit the wearer's excretion opening, especially the labia, and reduce leakage Can do.
- the cushion part preferably has a maximum thickness of about 50% or more after absorbing 2 g of equine EDTA blood and before absorbing horse EDTA blood, and has a maximum thickness of about 60% or more. More preferably, and even more preferably a maximum thickness of about 70% or more.
- the reason for dropping 2 g of equine EDTA blood is that the amount of menstrual blood excreted at one time by humans is said to be approximately 2 g.
- 2 g of equine EDTA blood is dripped on the entire cushion part using a pipette.
- the cushion part contains a water-repellent material
- the equine EDTA blood is difficult to enter the cushion part. In such a case, equine EDTA blood may be absorbed by the cushion portion while pressurizing the cushion portion.
- the maximum thickness of the cushion part after absorbing 2 g of equine EDTA blood can be measured after 1 minute has elapsed since all of the equine EDTA blood has been absorbed. Further, the maximum thickness of the cushion portion can be measured using the above-described two-dimensional laser displacement meter. The EDTA blood will be described later.
- the absorbent article has a curved structure that curves with the middle and high portions facing inward. It is considered that when the absorbent article has a curved structure, the absorbent article fits more with the curve of the wearer's body and absorbed menstrual blood is less likely to leak.
- the curved structure can be formed, for example, by passing an elastic member, for example, a rubber thread, a stretchable film, etc., on both sides in the longitudinal direction of the absorbent article, and applying tension to both sides in the longitudinal direction of the absorbent article. .
- the liquid-permeable top sheet has a plurality of ridges and a plurality of grooves extending in the longitudinal direction of the absorbent article on the skin contact surface (book).
- a top sheet having a plurality of ridges and a plurality of grooves extending in the longitudinal direction of the absorbent article may be simply referred to as a top sheet having a ridge groove structure).
- the top sheet can be produced according to the methods described in JP-A-2008-025078, JP-A-2008-025079 and the like.
- a top sheet having a ridge groove structure can be produced according to the method described in JP2011-226101, JP2011-226011, or the like.
- the top sheet having the ridge groove structure is a pair of gear rolls having a rotation axis perpendicular to the conveying direction, and a gap between the plurality of teeth arranged on the outer peripheral surfaces of the gear rolls while meshing with each other. It can be formed by fluid treatment through the top sheet to be treated.
- the draw ratio of the gear roll is preferably about 105% or more, more preferably about 105 to about 500%, further preferably about 120 to 300%, and further preferably about 130%. About 200%.
- the stretch ratio is less than about 105%, the stretchability of the top sheet is insufficient, the cushion part is easily crushed during the manufacture of absorbent articles, and when the stretch ratio is greater than about 500%, There is a tendency that the top sheet is easily torn during the manufacture of the property article.
- the said draw ratio is the following formula when the gear pitch is P and the gear biting depth is D: Means the value calculated by.
- the liquid-permeable top sheet has a plurality of slits.
- the slit can be widened and the cushion portion can be prevented from being excessively crushed during the manufacture of the absorbent article.
- the top sheet having the plurality of slits can be formed by passing the top sheet through a slit roll in which vertically long slits are arranged in a staggered manner.
- the top sheet having the plurality of slits can be manufactured, for example, as described in JP-T-2002-528174.
- the liquid-permeable top sheet has a plurality of pin opening portions.
- a top sheet having a ridge groove structure, slits, pin openings, etc. has an excessive cushion part due to a change in the shape of the groove structure of the top sheet, opening / closing of the slit and pin openings, etc. during manufacture of the absorbent article. Can be prevented from being crushed. From this point of view, it is preferable that the ridge groove structure, slit, pin opening portion, etc. of the top sheet are present at least in the portion in contact with the cushion portion, i.e., the portion constituting the middle-high portion. May be present.
- the absorbent article of the present disclosure can have any shape such as a rectangle, an ellipse, a saddle, and the like, and may have a so-called flap that prevents deviation from clothes, for example, shorts.
- the size of the absorbent article of the present disclosure is preferably A longitudinal length of about 100 to about 500 mm, more preferably about 120 to about 350 mm, and more preferably about 150 to about 250 mm, preferably about 40 to about 200 mm, more preferably about 45 to about 180 mm, and further Preferably, it has a length in the width direction of about 50 to 100 mm.
- the absorbent body preferably has a longitudinal length of about 80 to about 350 mm, more preferably about 100 to 300 mm, and more preferably about 120 to 250 mm.
- the absorbent body preferably has a longitudinal length of about 80 to about 350 mm, more preferably about 100 to 300 mm, and more preferably about 120 to 250 mm.
- the buttock is a part that changes greatly when the wearer walks, sits, etc., and when a twist occurs in the absorber in contact with the buttock, the absorbent in the excretory opening, particularly the part in contact with the labia
- the absorbent body preferably has a length in the width direction of about 30 to about 100 mm, more preferably about 35 to about 80 mm, and more preferably about 40 to about 70 mm. If the width of the absorbent body is excessively larger than the width of the wearer's crotch, the absorbent body is deformed, causing menstrual blood to spread to other areas and / or transferred, and the absorbed menstrual blood leaks. Because there are cases.
- the mid-high section has an IOB of about 0.00 to about 0.60, a melting point of about 45 ° C. or less, and about 0.00 to about 100 g of water at 25 ° C.
- IOB Inorganic Organic Balance
- IOB is an index indicating a balance between hydrophilicity and lipophilicity.
- Oda et al. IOB value calculated by inorganic value / organic value.
- the inorganic value and the organic value are represented by Fujita Minoru, “Prediction of organic compounds and conceptual diagram of organic compounds” in the field of chemistry Vol. 11, no. 10 (1957) p. 719-725).
- Table 1 summarizes the organic and inorganic values of the major groups by Mr. Fujita.
- the IOB is about 0.00 to about 0.60, preferably about 0.00 to about 0.50, and preferably about 0.00 to about 0.40. More preferred is about 0.00 to about 0.30. This is because the lower the IOB, the higher the organicity and the higher the affinity with blood cells.
- melting point means a peak top temperature of an endothermic peak when changing from a solid state to a liquid state when measured with a differential scanning calorimeter at a heating rate of 10 ° C./min.
- the melting point can be measured using, for example, a DSC-60 type DSC measuring apparatus manufactured by Shimadzu Corporation.
- the blood modifying agent may be liquid at room temperature or solid as long as it has a melting point of about 45 ° C. or lower, that is, whether the melting point is about 25 ° C. or higher, or less than about 25 ° C. Well, and can have a melting point of, for example, about ⁇ 5 ° C., about ⁇ 20 ° C., and the like. The reason why the melting point of the blood modifying agent is about 45 ° C. or less will be described later.
- the blood modifying agent has a lower melting point, but preferably has a low vapor pressure.
- the blood pressure of the blood modifying agent is preferably about 0 to about 200 Pa, more preferably about 0 to about 100 Pa, and about 0 to about 10 Pa at 25 ° C. (1 atm). More preferably, it is more preferably from about 0 to about 1 Pa, and even more preferably from about 0.0 to about 0.1 Pa.
- the vapor pressure is preferably about 0 to about 700 Pa at 40 ° C. (1 atm), and is about 0 to about 100 Pa.
- the melting point of the blood modifying agent can be properly used according to the climate, the length of wearing time, and the like. For example, in an area where the average temperature is about 10 ° C. or less, even when the menstrual blood is excreted and then cooled by the ambient temperature by adopting a blood modifying agent having a melting point of about 10 ° C. or less. It is considered that the blood modifying agent can stably modify blood. Further, when the absorbent article is used for a long time, the melting point of the blood modifying agent is preferably higher in the range of 45 ° C. or lower. This is because the blood modifying agent is difficult to move even when it is worn for a long time, and is hardly affected by sweat, friction at the time of wearing, and the like.
- the water solubility of 0.00-0.05 g was obtained by adding 0.05 g of sample to 100 g of deionized water at 25 ° C., leaving it to stand for 24 hours, and after 24 hours, gently stirring as necessary. Then, it can be measured by visually evaluating whether or not the sample is dissolved.
- dissolution includes a case where the sample is completely dissolved in deionized water to form a uniform mixture and a case where the sample is completely emulsified.
- “Complete” means that there is no lump of sample in deionized water.
- top sheets coated with surfactants are well-suited to hydrophilic components (blood plasma, etc.) in blood, but rather leave blood on the top sheet. There is a tendency to work. Since the blood modifying agent has low water solubility, it is considered that blood can be quickly transferred to the absorbent body without remaining on the top sheet, unlike conventionally known surfactants.
- solubility in 100 g of water at 25 ° C. may be simply referred to as “water solubility”.
- a weight average molecular weight means the value of polystyrene conversion calculated
- GPC measurement conditions include the following. Model :( stock) manufactured by Hitachi High-Technologies high-performance liquid chromatogram Lachrom Elite Column: SHODEX KF-801, KF-803 and KF-804 manufactured by Showa Denko K.K. Eluent: THF Flow rate: 1.0 mL / min Driving amount: 100 ⁇ L Detection: RI (differential refractometer)
- the weight average molecular weight described in the Example of this specification is measured on the said conditions.
- the blood modifying agent is preferably the following (i) ⁇ (iii), (I) hydrocarbons, (Ii) from (ii-1) a hydrocarbon moiety and (ii-2) a carbonyl group (—CO—) and an oxy group (—O—) inserted between the CC single bonds of the hydrocarbon moiety.
- the hydrocarbon moiety A compound having one or a plurality of the same or different groups selected from the group consisting of a carboxyl group (—COOH) and a hydroxyl group (—OH), which replaces a hydrogen atom; As well as any combination thereof.
- hydrocarbon means a compound composed of carbon and hydrogen, and a chain hydrocarbon, for example, a paraffinic hydrocarbon (also referred to as an alkane, which does not include a double bond and a triple bond).
- a paraffinic hydrocarbon also referred to as an alkane, which does not include a double bond and a triple bond.
- Olefinic hydrocarbons including one double bond, also referred to as alkene
- acetylenic hydrocarbons including one triple bond, also referred to as alkyne
- hydrocarbons containing two or more bonds selected from the above and cyclic hydrocarbons such as aromatic hydrocarbons and alicyclic hydrocarbons.
- the hydrocarbon is preferably a chain hydrocarbon and an alicyclic hydrocarbon, more preferably a chain hydrocarbon, a paraffinic hydrocarbon, an olefinic hydrocarbon, and two double bonds. More preferred are hydrocarbons (not including triple bonds), and more preferred are paraffinic hydrocarbons.
- the chain hydrocarbon includes a straight chain hydrocarbon and a branched chain hydrocarbon.
- each oxy group (—O—) is not adjacent. Therefore, the compounds (ii) and (iii) do not include compounds having a continuous oxy group (so-called peroxides).
- At least one hydrogen atom in the hydrocarbon moiety is more than a hydroxyl group (-) than in a compound in which at least one hydrogen atom in the hydrocarbon moiety is substituted with a carboxyl group (-COOH).
- Compounds substituted with OH) are preferred.
- Table 1 since the carboxyl group binds to menstrual metals and the like, and the inorganic value increases significantly from 150 to 400 or more, the blood modifying agent having a carboxyl group is used at the time of use. This is because the value of IOB exceeds about 0.60, and the affinity with blood cells may be reduced.
- the blood modifying agent is more preferably the following (i ′) to (iii ′), (I ′) hydrocarbon, (Ii ′) (ii′-1) a hydrocarbon moiety and (ii′-2) a carbonyl bond (—CO—), an ester bond (—COO) inserted between the C—C single bonds of the hydrocarbon moiety.
- the blood modifying agent preferably has about 1.8 or less carbonyl bonds (—CO—) and 2 or less ester bonds (—COO—) per 10 carbon atoms in the hydrocarbon moiety. About 1.5 or less carbonate bonds (—OCOO—), about 6 or less ether bonds (—O—), about 0.8 or less carboxyl groups (—COOH), and / or hydroxyl groups (—OH) ) In a compound having about 1.2 or less.
- the blood modifying agent is more preferably the following (A) to (F), (A) (A1) a compound having a chain hydrocarbon moiety and 2 to 4 hydroxyl groups replacing hydrogen atoms in the chain hydrocarbon moiety, (A2) a chain hydrocarbon moiety, and the chain An ester with a compound having one carboxyl group for substituting a hydrogen atom in the hydrocarbon moiety, (B) (B1) a compound having a chain hydrocarbon moiety and 2 to 4 hydroxyl groups replacing hydrogen atoms in the chain hydrocarbon moiety, (B2) a chain hydrocarbon moiety, and the chain An ether with a compound having one hydroxyl group replacing a hydrogen atom of the hydrocarbon moiety, (C) (C1) a carboxylic acid, a hydroxy acid, an alkoxy acid or an oxo acid containing a chain hydrocarbon moiety and 2 to 4 carboxyl groups replacing a hydrogen atom in the chain hydrocarbon moiety; C2) an ester of a compound having a chain hydrocarbon mo
- (A1) A compound having a chain hydrocarbon moiety and 2 to 4 hydroxyl groups replacing hydrogen atoms in the chain hydrocarbon moiety (hereinafter sometimes referred to as “compound (A1)”)
- a chain hydrocarbon tetraol such as an alkanetetraol, such as pentaerythritol
- a chain hydrocarbon triol such as an alkanetriol, such as glycerine
- a chain hydrocarbon diol such as an alkanediol, such as, for example, Glycol.
- Examples of the compound (A2) having a chain hydrocarbon moiety and one carboxyl group that replaces the hydrogen atom of the chain hydrocarbon moiety include: , Compounds in which one hydrogen atom on a hydrocarbon is substituted with one carboxyl group (—COOH), for example, fatty acids.
- Examples of the compound (A) include (a 1 ) an ester of a chain hydrocarbon tetraol and at least one fatty acid, (a 2 ) an ester of a chain hydrocarbon triol and at least one fatty acid, and (a 3 ) Esters of chain hydrocarbon diols with at least one fatty acid.
- ester of (a 1 ) chain hydrocarbon tetraol and at least one fatty acid examples include the following formula (1): Tetraesters of pentaerythritol and fatty acids of the following formula (2): Triesters of pentaerythritol and fatty acids of the following formula (3): Diester of pentaerythritol and fatty acid of the following formula (4): And monoesters of pentaerythritol and fatty acids. (Wherein R 1 to R 4 are each a chain hydrocarbon)
- the ester of pentaerythritol and fatty acid has the above-mentioned IOB, melting point and water solubility.
- a saturated fatty acid for example, a C 2 to C 30 saturated fatty acid, for example, acetic acid (C 2 ) (C 2 represents the number of carbon atoms, R 1 C, R 2 C, R 3 C or R 4 C, the same applies hereinafter), propanoic acid (C 3 ), butanoic acid (C 4 ) and isomers thereof such as 2-methylpropanoic acid (C 4 ), Pentanoic acid (C 5 ) and isomers thereof such as 2-methylbutanoic acid (C 5 ), 2,2-dimethylpropanoic acid (C 5 ), hexanoic acid (C 6 ), heptanoic acid (C 7 ), octanoic acid (C 8) Beauty isomers thereof, e.g., 2-ethylhexanoic acid (C 8), nonanoic acid (C 9), decanoic acid (C 10), dode
- the fatty acid can also be an unsaturated fatty acid.
- unsaturated fatty acid include C 3 to C 20 unsaturated fatty acids such as monounsaturated fatty acids such as crotonic acid (C 4 ), myristoleic acid (C 14 ), palmitoleic acid (C 16 ), Oleic acid (C 18 ), elaidic acid (C 18 ), vaccenic acid (C 18 ), gadoleic acid (C 20 ), eicosenoic acid (C 20 ), etc., diunsaturated fatty acids such as linoleic acid (C 18 ), Triunsaturated fatty acids such as eicosadienoic acid (C 20 ), such as linolenic acid, such as ⁇ -linolenic acid (C 18 ) and ⁇ -linolenic acid (C 18 ), pinolenic acid (C 18 ), eleostearic acid, For example, ⁇ -eleostearic acid (C
- the ester of pentaerythritol and fatty acid is an ester of pentaerythritol and a fatty acid derived from a saturated fatty acid, that is, an ester of pentaerythritol and a saturated fatty acid, considering the possibility of modification by oxidation or the like. preferable.
- the ester of pentaerythritol and fatty acid is preferably a diester, triester or tetraester, more preferably a triester or tetraester, in order to reduce IOB and make it more hydrophobic. And tetraesters are more preferred.
- the total number of carbon atoms of the fatty acid constituting the tetraester of pentaerythritol and fatty acid that is, in the above formula (1), R 1 C, R 2 C, R 3 C and When the total number of carbon atoms in the R 4 C portion is 15, IOB is 0.60. Therefore, when the total number of carbon atoms of the fatty acid constituting the tetraester of pentaerythritol and fatty acid is about 15 or more, the IOB satisfies the requirement of about 0.00 to about 0.60.
- tetraester of pentaerythritol and fatty acid for example, pentaerythritol, hexanoic acid (C 6 ), heptanoic acid (C 7 ), octanoic acid (C 8 ), for example, 2-ethylhexanoic acid (C 8 ), And tetraesters with nonanoic acid (C 9 ), decanoic acid (C 10 ) and / or dodecanoic acid (C 12 ).
- the total number of carbon atoms of the fatty acid constituting the triester of pentaerythritol and fatty acid that is, in the above formula (2), R 1 C, R 2 C and R 3 C moieties
- IOB is 0.58. Therefore, when the total number of carbon atoms of the fatty acid constituting the triester of pentaerythritol and fatty acid is about 19 or more, the IOB satisfies the requirement of about 0.00 to about 0.60.
- the total number of carbon atoms of the fatty acid constituting the diester of pentaerythritol and fatty acid that is, the total number of carbon atoms of the R 1 C and R 2 C moieties in the above formula (3) is In the case of 22, the IOB is 0.59. Accordingly, when the total number of carbon atoms of the fatty acid constituting the diester of pentaerythritol and fatty acid is about 22 or more, the IOB satisfies the requirement of about 0.00 to about 0.60.
- the number of carbons of the fatty acid constituting the monoester of pentaerythritol and fatty acid that is, in the above formula (4), the IOB is 25 when the carbon number of the R 1 C portion is 25. 0.60. Therefore, when the fatty acid constituting the monoester of pentaerythritol and fatty acid has a carbon number of about 25 or more, the IOB satisfies the requirement of about 0.00 to about 0.60. In the above calculation, the influence of double bond, triple bond, iso branch, and tert branch is not taken into consideration.
- esters of pentaerythritol and fatty acids examples include Unistar H-408BRS, H-2408BRS-22 (mixed product) and the like (manufactured by NOF Corporation).
- ester of the chain hydrocarbon triol and at least one fatty acid examples include the following formula (5): Triester of glycerin and fatty acid of the following formula (6): Diesters of glycerin and fatty acids and the following formula (7): (Wherein R 5 to R 7 are each a chain hydrocarbon) And monoesters of glycerin and fatty acids.
- the ester of the glycerin and the fatty acid constituting the ester of the glycerin and the fatty acid, as long as the ester of the glycerin and the fatty acid satisfies the requirements for the IOB, melting point and water solubility,
- the fatty acids listed in “Ester of (a 1 ) chain hydrocarbon tetraol and at least one fatty acid”, that is, saturated fatty acids and unsaturated fatty acids, and the like are modified by oxidation or the like.
- it is preferable to use an ester of glycerin and a fatty acid derived from a saturated fatty acid that is, an ester of glycerin and a saturated fatty acid.
- ester of glycerin and fatty acid is preferably a diester or triester, and more preferably a triester, in order to reduce IOB and make it more hydrophobic.
- the triester of glycerin and a fatty acid is also referred to as a triglyceride.
- triester of glycerin and octanoic acid C 8
- triester of glycerin and decanoic acid C 10
- glycerin and dodecanoic acid C 12
- triesters of glycerin and 2 or 3 fatty acids and mixtures thereof.
- Examples of the triesters of glycerin and two or more fatty acids include triesters of glycerin and octanoic acid (C 8 ) and decanoic acid (C 10 ), glycerin, octanoic acid (C 8 ), and decane.
- Examples thereof include triesters with (C 16 ) and octadecanoic acid (C 18 ).
- the total number of carbon atoms of the fatty acid constituting the triester of glycerin and fatty acid that is, R 5 C in formula (5) in order to make the melting point about 45 ° C. or less.
- R 6 C and R 7 C moieties preferably have a total carbon number of about 40 or less.
- the total number of carbon atoms of the fatty acid constituting the triester of glycerin and fatty acid that is, in the formula (5), R 5 C, R 6 C and R 7 C moieties.
- the IOB is 0.60. Therefore, when the total number of carbon atoms of the fatty acid constituting the triester of glycerin and fatty acid is about 12 or more, the IOB satisfies the requirement of about 0.00 to about 0.60.
- the triester of glycerin and a fatty acid is a so-called fat and is a component that can constitute a human body, and thus is preferable from the viewpoint of safety.
- triesters of glycerin and fatty acids include tricoconut oil fatty acid glyceride, NA36, panacet 800, panacet 800B and panacet 810S, and tri-C2L oil fatty acid glyceride and tri-CL oil fatty acid glyceride (above, manufactured by NOF Corporation). ) And the like.
- the diester of glycerin and fatty acid is also called diglyceride.
- diester of glycerin and decanoic acid (C 10 ) diester of glycerin and dodecanoic acid (C 12 ), glycerin and hexadecanoic acid (C 16 ) Examples include diesters, diesters of glycerin and two fatty acids, and mixtures thereof.
- the total number of carbon atoms of the fatty acid constituting the diester of glycerin and fatty acid that is, the total number of carbon atoms of the R 5 C and R 6 C moieties in the formula (6) is 16.
- the IOB is 0.58. Therefore, when the total number of carbon atoms of the fatty acid constituting the diester of glycerin and fatty acid is about 16 or more, the IOB satisfies the requirement of about 0.00 to about 0.60.
- the monoester of the glycerin and the fatty acid is also referred to as a monoglyceride, and examples thereof include glycerin icosanoic acid (C 20 ) monoester, glycerin docosanoic acid (C 22 ) monoester, and the like.
- the monoester of glycerin and fatty acid the number of carbon atoms of the fatty acid constituting the monoester of glycerin and fatty acid, that is, when the carbon number of the R 5 C moiety in the formula (7) is 19, the IOB is 0.59. It becomes. Therefore, when the fatty acid constituting the monoester of glycerin and fatty acid has about 19 or more carbon atoms, the IOB satisfies the requirement of about 0.00 to about 0.60.
- ester of (a 3 ) chain hydrocarbon diol and at least one fatty acid examples include C 2 to C 6 chain hydrocarbon diols such as C 2 to C 6 glycols such as ethylene glycol, propylene glycol, butylene. Examples thereof include monoesters or diesters of glycol, pentylene glycol or hexylene glycol and a fatty acid.
- ester of the chain hydrocarbon diol and at least one fatty acid for example, the following formula (8): R 8 COOC k H 2k OCOR 9 (8) (Wherein k is an integer from 2 to 6 and R 8 and R 9 are each a chain hydrocarbon) A diester of a C 2 -C 6 glycol with a fatty acid and the following formula (9): R 8 COOC k H 2k OH (9) (Wherein k is an integer from 2 to 6 and R 8 is a chain hydrocarbon) And monoesters of C 2 -C 6 glycols and fatty acids.
- the fatty acid to be esterified (corresponding to R 8 COOH and R 9 COOH in formula (8) and formula (9)) is C 2 -C 6 glycol.
- an ester of a fatty acid satisfying the above requirements of IOB, melting point and water solubility for example, “(a 1 ) ester of chain hydrocarbon tetraol and at least one fatty acid”
- the fatty acids listed in the above that is, saturated fatty acids and unsaturated fatty acids are mentioned, and saturated fatty acids are preferred in consideration of the possibility of modification by oxidation or the like.
- the ester of a C 2 ⁇ C 6 glycols and fatty acid in view of the potential for degradation by oxidation and the like, derived from saturated fatty acids, esters of C 2 ⁇ C 6 glycols and fatty acid, Nachi Suwa, C 2 An ester of ⁇ C 6 glycol and saturated fatty acid is preferred.
- the ester of C 2 -C 6 glycol and fatty acid is an ester of glycol and fatty acid derived from glycol having a large carbon number, for example, butylene glycol, in order to reduce IOB and make it more hydrophobic.
- An ester of glycol and fatty acid derived from pentylene glycol or hexylene glycol is preferable.
- ester of C 2 -C 6 glycol and fatty acid is preferably a diester in order to reduce IOB and make it more hydrophobic.
- examples of commercial products of the ester of C 2 -C 6 glycol and fatty acid include Compol BL and Compol BS (manufactured by NOF Corporation).
- Compound (B1) Compounds having a chain hydrocarbon moiety and 2 to 4 hydroxyl groups replacing hydrogen atoms in the chain hydrocarbon moiety are listed as “Compound (A)” as Compound (A1). For example, pentaerythritol, glycerin, and glycol.
- Examples of the compound (B2) having a chain hydrocarbon moiety and one hydroxyl group replacing the hydrogen atom of the chain hydrocarbon moiety include: , Compounds in which one hydrogen atom of a hydrocarbon is replaced by one hydroxyl group (—OH), for example, aliphatic monohydric alcohols, for example, saturated aliphatic monohydric alcohols and unsaturated aliphatic monohydric alcohols Is mentioned.
- saturated aliphatic monohydric alcohol examples include C 1 to C 20 saturated aliphatic monohydric alcohols such as methyl alcohol (C 1 ) (C 1 represents the number of carbon atoms, the same shall apply hereinafter), ethyl alcohol ( C 2 ), propyl alcohol (C 3 ) and isomers thereof such as isopropyl alcohol (C 3 ), butyl alcohol (C 4 ) and isomers thereof such as sec-butyl alcohol (C 4 ) and tert-butyl alcohol (C 4 ), pentyl alcohol (C 5 ), hexyl alcohol (C 6 ), heptyl alcohol (C 7 ), octyl alcohol (C 8 ) and isomers thereof such as 2-ethylhexyl alcohol (C 8 ), nonyl alcohol (C 9), decyl alcohol (C 10), dodecyl alcohol (C 12), tetradecyl alcohol (C 14), Hexadecyl alcohol (C 16), to
- Examples of the unsaturated aliphatic monohydric alcohol include those obtained by substituting one of the C—C single bonds of the saturated aliphatic monohydric alcohol with a C ⁇ C double bond, such as oleyl alcohol. It is commercially available from Shin Nippon Rika Co., Ltd. under the names of the Jamaica Coal series and the Angelo All series.
- Examples of the compound (B) include (b 1 ) ethers of chain hydrocarbon tetraol and at least one aliphatic monohydric alcohol, such as monoether, diether, triether and tetraether, preferably diether, triether.
- Ethers and tetraethers more preferably triethers and tetraethers, and even more preferably tetraethers, ethers of (b 2 ) chain hydrocarbon triols and at least one aliphatic monohydric alcohol, such as monoethers, diethers and Triethers, preferably diethers and triethers, and more preferably triethers, and (b 3 ) ethers of chain hydrocarbon diols with at least one aliphatic monohydric alcohol, such as monoethers and diethers, and preferably Diether It is below.
- Examples of the ether of the chain hydrocarbon tetraol and at least one aliphatic monohydric alcohol include, for example, the following formulas (10) to (13): (In the formula, R 10 to R 13 are each a chain hydrocarbon.) And tetraethers, triethers, diethers and monoethers of pentaerythritol and aliphatic monohydric alcohols.
- Examples of the ether of the chain hydrocarbon triol and at least one aliphatic monohydric alcohol include, for example, the following formulas (14) to (16): (Wherein, R 14 ⁇ R 16 each represent a chain hydrocarbon.) And triether, diether and monoether of glycerin and aliphatic monohydric alcohol.
- Examples of the ether of the chain hydrocarbon diol and at least one aliphatic monohydric alcohol include the following formula (17): R 17 OC n H 2n OR 18 (17) (Wherein n is an integer from 2 to 6 and R 17 and R 18 are each a chain hydrocarbon) A diether of a C 2 -C 6 glycol and an aliphatic monohydric alcohol, and the following formula (18): R 17 OC n H 2n OH (18) (Wherein n is an integer from 2 to 6 and R 17 is a chain hydrocarbon) Monoether of C 2 ⁇ C 6 glycol and an aliphatic monohydric alcohol and the like.
- the total number of carbon atoms of the aliphatic monohydric alcohol constituting the tetraether of pentaerythritol and aliphatic monohydric alcohol that is, in the above formula (10)
- the IOB is 0.44. Therefore, when the total number of carbon atoms of the aliphatic monohydric alcohol constituting the tetraether of pentaerythritol and aliphatic monohydric alcohol is about 4 or more, the requirement that the IOB is about 0.00 to about 0.60 Meet.
- the total number of carbon atoms of the aliphatic monohydric alcohol constituting the triether of pentaerythritol and aliphatic monohydric alcohol that is, in the above formula (11)
- IOB is 0.57. Therefore, when the total number of carbon atoms of the aliphatic monohydric alcohol constituting the triether of pentaerythritol and aliphatic monohydric alcohol is about 9 or more, the requirement that the IOB is about 0.00 to about 0.60 Meet.
- the total number of carbon atoms of the aliphatic monohydric alcohol constituting the diether of pentaerythritol and aliphatic monohydric alcohol that is, in the formula (12), R 10
- the IOB is 0.60. Therefore, when the total number of carbon atoms of the aliphatic monohydric alcohol constituting the diether of pentaerythritol and aliphatic monohydric alcohol is about 15 or more, the IOB is about 0.00 to about 0.60. Fulfill.
- the carbon number of the aliphatic monohydric alcohol constituting the monoether of pentaerythritol and aliphatic monohydric alcohol that is, in the above formula (13), R 10
- the IOB is 0.59. Therefore, when the aliphatic monohydric alcohol constituting the monoether of pentaerythritol and aliphatic monohydric alcohol has about 22 or more carbon atoms, the IOB satisfies the requirement of about 0.00 to about 0.60. .
- the total number of carbon atoms of the aliphatic monohydric alcohol constituting the triether of glycerin and aliphatic monohydric alcohol that is, in the formula (14), R
- the IOB is 0.50. Therefore, when the total number of carbon atoms of the aliphatic monohydric alcohol constituting the triether of the glycerin and the aliphatic monohydric alcohol is about 3 or more, the IOB is about 0.00 to about 0.60. Fulfill.
- the total number of carbon atoms of the aliphatic monohydric alcohol constituting the diether of glycerin and aliphatic monohydric alcohol that is, in the formula (15), R 14 and R 15
- the IOB is 0.58. Therefore, when the total number of carbon atoms of the aliphatic monohydric alcohol constituting the diether of glycerin and aliphatic monohydric alcohol is about 9 or more, the IOB satisfies the requirement of about 0.00 to about 0.60. .
- the carbon number of the aliphatic monohydric alcohol constituting the monoether of glycerin and aliphatic monohydric alcohol that is, the carbon of R 14 moiety in the formula (16).
- the IOB is 0.58. Accordingly, when the aliphatic monohydric alcohol constituting the monoether of glycerin and aliphatic monohydric alcohol has about 16 or more carbon atoms, the IOB satisfies the requirement of about 0.00 to about 0.60.
- the IOB is about 0. Satisfies the requirements of .00 to about 0.60.
- Compound (B) can be produced by dehydrating condensation of compound (B1) and compound (B2) in the presence of an acid catalyst.
- C1 Carboxylic acids, hydroxy acids, alkoxy acids or oxo acids (hereinafter referred to as “compounds”) containing a chain hydrocarbon moiety and 2 to 4 carboxyl groups that replace the hydrogen atoms of the chain hydrocarbon moiety.
- C1) may be referred to as, for example, a chain hydrocarbon carboxylic acid having 2 to 4 carboxyl groups, such as a chain hydrocarbon dicarboxylic acid such as an alkanedicarboxylic acid such as ethanedioic acid.
- Examples include rubonic acids such as alkanetetracarboxylic acids such as butanetetraacid, pentanetetraacid, hexanetetraacid, heptanetetraacid, octanetetraacid, nonanetetraacid and decanetetra
- the compound (C1) includes a chain hydrocarbon hydroxy acid having 2 to 4 carboxyl groups, for example, a chain chain having 2 to 4 carboxyl groups such as malic acid, tartaric acid, citric acid, isocitric acid and the like. Hydrocarbon alkoxy acids such as O-acetylcitric acid and chain hydrocarbon oxoacids having 2 to 4 carboxyl groups are included.
- C2 Examples of the compound having a chain hydrocarbon moiety and one hydroxyl group substituting a hydrogen atom of the chain hydrocarbon moiety include those listed in the section of “Compound (B)”, for example, An aliphatic monohydric alcohol is mentioned.
- compound (D) a compound having any one bond selected from the group consisting of a carbonate bond (—OCOO—)
- compound (D) a compound having any one bond selected from the group consisting of a carbonate bond (—OCOO—)
- compound (D) aliphatic
- examples include ethers of monohydric alcohols and aliphatic monohydric alcohols, (d 2 ) dialkyl ketones, esters of (d 3 ) fatty acids and aliphatic monohydric alcohols, and (d 4 ) dialkyl carbonates.
- the ether As the aliphatic monohydric alcohol constituting the ether (corresponding to R 19 OH and R 20 OH in the formula (19)), the ether satisfies the requirements for the IOB, melting point and water solubility.
- the aliphatic monohydric alcohol listed in the section of “Compound (B)” is not particularly limited.
- the total number of carbon atoms of the aliphatic monohydric alcohol constituting the ether that is, the number of carbon atoms of R 19 and R 20 in the above formula (19). Since the IOB is 0.50 when the sum of the two is 2, the IOB requirement is satisfied if the total number of carbon atoms is about 2 or more. However, when the total number of carbon atoms is about 6, the water solubility is as high as about 2 g, which is problematic from the viewpoint of vapor pressure. In order to satisfy the requirement of water solubility of about 0.00 to about 0.05 g, the total number of carbon atoms is preferably about 8 or more.
- dialkylketone As the dialkyl ketone, the following formula (20): R 21 COR 22 (20) (Wherein R 21 and R 22 are each an alkyl group) The compound which has is mentioned.
- the IOB requirement is satisfied if the total number of carbon atoms is about 5 or more.
- the water solubility is as high as about 2 g. Therefore, in order to satisfy the requirement of water solubility of about 0.00 to about 0.05 g, the total number of carbon atoms is preferably about 8 or more.
- the carbon number is preferably about 10 or more, and more preferably about 12 or more.
- the melting point is about ⁇ 50 ° C.
- the vapor pressure is about 230 Pa at 20 ° C.
- the dialkyl ketone can be obtained by a known method, for example, by oxidizing a secondary alcohol with chromic acid or the like.
- ester of the fatty acid and the aliphatic monohydric alcohol include the following formula (21): R 23 COOR 24 (21) (Wherein, R 23 and R 24, each represent a chain hydrocarbon) The compound which has is mentioned.
- Examples of the fatty acid constituting the ester are listed in “(a 1 ) ester of chain hydrocarbon tetraol and at least one fatty acid”.
- Fatty acids that is, saturated fatty acids or unsaturated fatty acids can be mentioned, and saturated fatty acids are preferable in consideration of the possibility of modification by oxidation or the like.
- Examples of the aliphatic monohydric alcohol constituting the ester include the aliphatic monohydric alcohols listed in the section “Compound (B)”.
- the total number of carbon atoms of the fatty acid and the aliphatic monohydric alcohol is 5
- the above IOB requirement is satisfied when the total number of carbon atoms in the R 23 C and R 24 portions is about 5 or more.
- the total number of carbon atoms is preferably about 12 or more. If the total number of carbon atoms is about 11 or more, the water solubility can satisfy the requirement of about 0.00 to about 0.05 g.
- ester of the fatty acid and the aliphatic monohydric alcohol examples include, for example, an ester of dodecanoic acid (C 12 ) and dodecyl alcohol (C 12 ), tetradecanoic acid (C 14 ), and dodecyl alcohol (C 12 ).
- ester of the above fatty acids and aliphatic monohydric alcohols examples include Electol WE20 and Electol WE40 (manufactured by NOF Corporation).
- the dialkyl carbonate since the IOB is 0.57 when the total number of carbon atoms of R 25 and R 26 is 6, if the total number of carbon atoms of R 25 and R 26 is about 6 or more, Satisfy requirements. In consideration of water solubility, the total number of carbon atoms of R 25 and R 26 is preferably about 7 or more, and more preferably about 9 or more.
- the dialkyl carbonate can be synthesized by a reaction between phosgene and an alcohol, a reaction between a chlorinated formate and an alcohol or an alcoholate, and a reaction between silver carbonate and an alkyl iodide.
- Examples of the polyoxy C 2 -C 6 alkylene glycol, or an ester or ether thereof include (e 1 ) polyoxy C 2 -C 6 alkylene glycol, (e 2 ) polyoxy C An ester of 2 to C 6 alkylene glycol and at least one fatty acid, (e 3 ) an ether of polyoxy C 2 to C 6 alkylene glycol and at least one aliphatic monohydric alcohol, (e 4 ) polyoxy C 2 to C 6 Esters of alkylene glycol with chain hydrocarbon tetracarboxylic acid, chain hydrocarbon tricarboxylic acid, or chain hydrocarbon dicarboxylic acid, and (e 5 ) polyoxy C 2 -C 6 alkylene glycol and chain hydrocarbon tetra Examples include ethers with all, chain hydrocarbon triols, or chain hydrocarbon diols.
- the oxy C 2 -C 6 alkylene skeleton is preferably an oxypropylene skeleton, an oxybutylene skeleton, an oxypentylene skeleton, or an oxyhexylene skeleton from the viewpoint of lowering the IOB of the polyoxy C 2 -C 6 alkylene glycol.
- An oxybutylene skeleton, an oxypentylene skeleton, or an oxyhexylene skeleton is more preferable.
- polyoxy C 2 -C 6 alkylene glycol does not include homopolymers of ethylene glycol, ethylene glycol as a block or random copolymer with other glycols as (e 1 ) polyoxy C 2- contained in C 6 alkylene glycol.
- the homopolymer of formula (23) may include a homopolymer of propylene glycol, butylene glycol, pentylene glycol or hexylene glycol. From the above, in formula (23), m is about 3 to about 6, more preferably about 4 to about 6, and n is 2 or more.
- the value of n is such that the polyoxy C 2 -C 6 alkylene glycol has an IOB of about 0.00 to about 0.60, a melting point of about 45 ° C. or less, and 100 g of water at 25 ° C. A value having a water solubility of about 0.00 to about 0.05 g.
- the weight average molecular weight of the polyoxy C 4 -C 6 alkylene glycol is preferably about 200 to about 10,000, more preferably about 250 to about 8,000, and even more preferably, It is in the range of about 250 to about 5,000.
- the weight average molecular weight of polyoxy C 3 alkylene glycol, ie, polypropylene glycol is preferably about 1,000 to about 10,000, more preferably about 3,000 to about 8 , 000, and more preferably in the range from about 4,000 to about 5,000. This is because, when the weight average molecular weight is less than about 1,000, the water solubility does not satisfy the requirement, and the higher the weight average molecular weight, the more the absorber transfer speed and the whiteness of the top sheet tend to improve.
- ester of polyoxy C 2 -C 6 alkylene glycol and at least one fatty acid examples include the OH terminal of the polyoxy C 2 -C 6 alkylene glycol described in the section “(e 1 ) polyoxy C 2 -C 6 alkylene glycol”. In which one or both of them are esterified with a fatty acid, that is, monoesters and diesters.
- Examples of the fatty acid to be esterified in the ester of polyoxy C 2 -C 6 alkylene glycol and at least one fatty acid are listed in “Ester of (a 1 ) chain hydrocarbon tetraol and at least one fatty acid”.
- Fatty acid that is, saturated fatty acid or unsaturated fatty acid, and saturated fatty acid is preferable in consideration of possibility of modification by oxidation or the like.
- Examples of commercially available esters of the above polyoxy C 2 -C 6 alkylene glycol and fatty acid include Wilbright cp9 (manufactured by NOF Corporation).
- Examples of the aliphatic monohydric alcohol to be etherified in the ether of polyoxy C 2 -C 6 alkylene glycol and at least one aliphatic monohydric alcohol include, for example, the aliphatic enumerated in the section of “Compound (B)”. A monohydric alcohol is mentioned.
- Esters of the above polyoxy C 2 -C 6 alkylene glycol and chain hydrocarbon tetracarboxylic acid, chain hydrocarbon tricarboxylic acid, or chain hydrocarbon dicarboxylic acid are commercially available, and chain hydrocarbon tetracarboxylic acid. It can be produced by polycondensing an oxy C 2 -C 6 alkylene glycol to an acid, a chain hydrocarbon tricarboxylic acid, or a chain hydrocarbon dicarboxylic acid under known conditions.
- chain hydrocarbon tetraol, chain hydrocarbon triol, and chain hydrocarbon diol to be etherified include those described in the section of “Compound (A)”, such as pentaerythritol, glycerin, and glycol. Is mentioned.
- Examples of commercially available ethers of the above polyoxy C 2 -C 6 alkylene glycol and chain hydrocarbon tetraol, chain hydrocarbon triol, or chain hydrocarbon diol include, for example, Unilube (trademark) 5TP-300KB, and And Uniol (trademark) TG-3000 and TG-4000 (manufactured by NOF Corporation).
- Unilube (trademark) 5TP-300KB is a compound obtained by polycondensation of 65 mol of propylene glycol and 5 mol of ethylene glycol to 1 mol of pentaerythritol, its IOB is 0.39, and its melting point is less than 45 ° C. Yes, and the water solubility was less than 0.05 g.
- Uniol TM TG-3000 is a compound obtained by polycondensation of 50 mol of propylene glycol with 1 mol of glycerin, its IOB is 0.42, its melting point is less than 45 ° C., and its water solubility is 0.05 g. And the weight average molecular weight was about 3,000.
- Uniol TM TG-4000 is a compound obtained by polycondensation of 70 mol of propylene glycol with 1 mol of glycerin, its IOB is 0.40, its melting point is less than 45 ° C., and its water solubility is 0.05 g. And the weight average molecular weight was about 4,000.
- the ether of the polyoxy C 2 -C 6 alkylene glycol and the chain hydrocarbon tetraol, the chain hydrocarbon triol, or the chain hydrocarbon diol is also a chain hydrocarbon tetraol, a chain hydrocarbon triol, or It can be produced by adding C 2 -C 6 alkylene oxide to a chain hydrocarbon diol under known conditions.
- the chain hydrocarbon Since the chain hydrocarbon has an inorganic value of 0, the IOB is 0.00 and the water solubility is approximately 0 g. Therefore, if the melting point is about 45 ° C. or less, the blood It can be included in the modifier.
- the chain hydrocarbon include (f 1 ) chain alkanes such as straight chain alkanes and branched chain alkanes. For example, in the case of straight chain alkanes, the melting point is about 45 ° C. or less. in view of the generally include those having a carbon number of 22 or less. Moreover, when the vapor pressure is taken into consideration, those having 13 or more carbon atoms are generally included.
- the melting point may be lower at the same number of carbons than that of a straight chain alkane. Therefore, those having 22 or more carbon atoms may be included.
- a commercial item of the above-mentioned hydrocarbon for example, Pearl Ream 6 (NOF Corporation) can be mentioned.
- the above-mentioned blood modifying agent is considered in detail together with the examples, but it has been found that it has at least an action of lowering blood viscosity and surface tension.
- menstrual blood to be absorbed by the absorbent article contains proteins such as the endometrial wall. Cheap. Therefore, menstrual blood to be absorbed by the absorbent article tends to have a high viscosity, and when the top sheet is a nonwoven fabric or a woven fabric, the menstrual blood is easily clogged between the fibers, and the wearer feels sticky. Almost, and menstrual blood diffuses on the surface of the topsheet, making it easier to leak.
- the mid-high portion includes a blood modifying agent that has been found to have at least an effect of lowering blood viscosity and surface tension
- the top sheet is a nonwoven or woven fabric, between the fibers of the top sheet
- menstrual blood is not easily clogged in the cushion portion, and menstrual blood can be quickly transferred from the top sheet to the absorbent body via the cushion portion.
- the absorbent article of the present disclosure has a cushion portion between the top sheet and the absorbent body in the middle and high portions, and therefore the interval between the top sheet and the absorbent body tends to be larger than that of conventional absorbent articles. There is. Therefore, when the middle and high parts contain a blood modifying agent, blood that has reached the top sheet can be quickly transferred to the absorbent body via the cushion part, which is considered to be more difficult to leak.
- a blood modifying agent having an IOB of about 0.00 to about 0.60 is highly organic and easily enters between blood cells, so that it stabilizes the blood cells and makes it difficult to form a monetary structure in the blood cells. It is considered possible. It is considered that the above-mentioned modifying agent stabilizes blood cells and makes it difficult to form a monetary structure on the blood cells, so that the absorbent body can easily absorb menstrual blood.
- the absorbent body can easily absorb menstrual blood.
- SAP acrylic superabsorbent polymer
- SAP when menstrual blood is absorbed, it is known that the collected blood cells cover the SAP surface and the SAP does not easily exhibit the absorption performance. It is considered that SAP stabilizes blood cells and can easily exhibit absorption performance.
- the blood modifying agent having a high affinity for red blood cells protects the red blood cell membrane, so that the red blood cells are hardly destroyed.
- liquid-permeable top sheet those usually used in the art can be employed without particular limitation, for example, a sheet-like material having a structure that allows blood to pass through, for example, an apertured film, A woven fabric, a nonwoven fabric, etc. are mentioned.
- the fibers constituting the woven fabric and the nonwoven fabric include natural fibers and chemical fibers.
- natural fibers include cellulose such as pulverized pulp and cotton.
- chemical fibers include rayon and fibrillar rayon. And regenerated cellulose, semi-synthetic cellulose such as acetate and triacetate, thermoplastic hydrophobic chemical fibers, and thermoplastic hydrophobic chemical fibers subjected to hydrophilic treatment.
- thermoplastic hydrophobic chemical fiber examples include single fibers such as polyethylene (PE), polypropylene (PP), and polyethylene terephthalate (PET), and fibers made of a graft polymer of PE and PP.
- nonwoven fabric examples include air-through nonwoven fabric, spunbond nonwoven fabric, point bond nonwoven fabric, spunlace nonwoven fabric, needle punch nonwoven fabric, melt blown nonwoven fabric, and combinations thereof (for example, SMS).
- liquid-impermeable back sheet examples include films containing PE, PP, etc., resin films having air permeability, those obtained by bonding a resin film having air permeability to a nonwoven fabric such as spunbond or spunlace, and composite materials such as SMS.
- a layer nonwoven fabric etc. are mentioned.
- a low density polyethylene (LDPE) film having a basis weight of about 15 to about 30 g / m 2 is preferred.
- Constituent elements of the absorbent core include, for example, hydrophilic fibers such as cellulose such as pulverized pulp and cotton, regenerated cellulose such as rayon and fibril rayon, semi-synthetic cellulose such as acetate and triacetate, particulate polymer, and fibrous polymer. , Thermoplastic hydrophobic chemical fibers, hydrophobized thermoplastic hydrophobic chemical fibers, and combinations thereof.
- a superabsorbent polymer for example, a granular material such as sodium acrylate copolymer can be cited.
- the core wrap is not particularly limited as long as it is liquid permeable and has a barrier property that does not allow the polymer absorber to permeate, and examples thereof include woven fabric and nonwoven fabric.
- examples of the woven fabric and non-woven fabric include natural fibers, chemical fibers, and tissues.
- the absorbent body As a second example of the absorbent body, one formed from an absorbent sheet or a polymer sheet can be cited, and the thickness is preferably about 0.3 to about 5.0 mm.
- the absorbent sheet and polymer sheet can be used without particular limitation as long as they are usually used in absorbent articles such as sanitary napkins.
- the blood modifying agent can be present at any location, such as the entire surface of the top sheet or the central region near the vaginal opening, with respect to the planar direction of the top sheet.
- the middle and high portions include the blood modifying agent
- the blood modifying agent when the liquid-permeable top sheet is formed from a nonwoven fabric or a woven fabric, the blood modifying agent is provided between the fibers of the nonwoven fabric or the woven fabric.
- the blood modifying agent is preferably adhered to the surface of the non-woven fiber in the form of droplets or particles, or the surface of the fiber can be covered.
- the middle and high portions when the liquid-permeable top sheet is formed from an apertured film, the blood modifying agent closes the aperture of the apertured film.
- the blood modifying agent can be attached in the form of droplets or particles on the surface of the apertured film, for example.
- the blood modifying agent closes the gap between the fibers of the nonwoven fabric or the woven fabric or the aperture of the apertured film, the absorbed liquid may be inhibited from transferring to the absorber.
- the blood modifying agent preferably has a large surface area in order to quickly migrate to absorbed blood, and is present in the form of droplets or particles.
- the blood modifying agent preferably has a small particle size.
- the middle and high portions contain the blood modifying agent
- these are hydrophilic agents. It is preferable that the surface is hydrophilized by coating or mixing. If the original material is hydrophilic, then it has an IOB of about 0.00 to about 0.60 and is coated with a highly organic and lipophilic modifier, so that the lipophilic region and hydrophilic The area will coexist sparsely. Thereby, it is considered that a certain absorption performance can be exhibited for menstrual blood composed of a hydrophilic component (plasma and the like) and a lipophilic component (blood cell and the like).
- a hydrophilic component plasma and the like
- a lipophilic component blood cell and the like
- the method for applying the blood modifying agent is not particularly limited, and is heated as necessary, for example, a non-contact coater, for example, a spiral. It can apply
- a non-contact type coater is preferable from the viewpoint that the droplet-like or particulate modifier is uniformly dispersed throughout and the point of not damaging the material.
- the blood modifying agent is applied from the control seam HMA gun as it is when it is liquid at room temperature, or heated to lower the viscosity, and heated so as to be liquefied when it is solid at room temperature. be able to. By increasing the air pressure of the control seam HMA gun, the particulate blood modifying agent can be applied.
- the blood modifying agent can be applied when producing a topsheet material, for example, a nonwoven fabric, or a production line for producing an absorbent article. Can also be applied.
- the middle and high portions include the blood modifying agent, from the viewpoint of suppressing capital investment, it is preferable to apply the blood modifying agent in the production line of the absorbent article, and the blood modifying agent is dropped off, In order to suppress contamination of the line, it is preferable to apply a blood modifying agent immediately downstream of the production line, specifically, immediately before the product is enclosed in the individual package.
- the blood modifying agent may also have an action as a lubricant.
- the top sheet is a nonwoven fabric, the friction between the fibers can be reduced, so that the flexibility of the entire nonwoven fabric is improved.
- a top sheet is a resin film, friction with a top sheet and skin can be reduced.
- the blood modifying agent preferably has a weight average molecular weight of about 2,000 or less, and more preferably has a weight average molecular weight of 1,000 or less. preferable. This is because when the weight average molecular weight increases, it becomes difficult to lower the viscosity of the blood modifying agent to a viscosity suitable for coating, and there is a case where the blood modifying agent should be diluted with a solvent. Moreover, when the weight average molecular weight is increased, the blood modifying agent is tacky, which may cause discomfort to the wearer.
- the absorbent article is suitable for absorbent articles intended to absorb blood, such as sanitary napkins and panty liners.
- an air-through non-woven fabric having a core-sheath structure formed from a polyethylene (PE) sheath and a polyethylene terephthalate (PET) core and made of a hydrophilic treated composite fiber (fineness: 2.2 dtex) Amount: 250 g / m 2 ) was prepared.
- the cushion portion before being incorporated into the absorbent article has a shape in which the projection in the thickness direction of the absorbent article is substantially rounded rectangle and the thickness is constant, as shown in FIG.
- the length in the longitudinal direction was 70 mm
- the length in the width direction was 30 mm
- the thickness was 22 mm.
- the absorbent body was formed by winding a mixture (basis weight: 250 g / m 2 ) of pulp and SAP blended at 90:10 (mass ratio) with a tissue (basis weight: 14 g / m 2 ).
- a back sheet a film containing PE (basis weight: 23 g / m 2 ) coated with an adhesive was prepared.
- the absorbent body, the cushion part, and the top sheet were laminated in order, and the absorbent body and the top sheet were squeezed to form a squeezed part as shown in FIGS. In addition, although the outer side of the cushion part was squeezed, the cushion part itself was not squeezed. Next, the absorbent article and the back sheet are bonded and cut as shown in FIGS. 1-1 was produced. Absorbent article no. In 1-1, the length in the longitudinal direction of the mid-high portion was about 70 mm, the length in the width direction of the mid-high portion was about 35 mm, and the maximum thickness of the cushion portion was about 10 mm. Also, the absorbent article No. The longitudinal length of 1-1 was about 176 mm, and the length in the width direction was about 80 mm.
- the cross-sectional shape of the cushion portion was arched as shown in FIGS. 3 and 4 due to the tensile force between the compressed top sheet and the absorbent body. Therefore, since the thickness of the outer peripheral part of the middle-high part is thinner than the thickness of the middle part of the middle-high part, the cushion part has a density of the cushion part in the middle part of the middle-high part. It is clear that it is higher.
- Panacet 810s manufactured by NOF Corporation, triester of glycerin and fatty acid
- the absorbent article No. 1-2 was produced.
- panacet 810s was in the form of fine particles and adhered to the surface of the fibers of the top and middle portions of the top sheet.
- Example 1 Absorbent article no. As a result of having 10 subjects wear 1-1, in a total of 18 tests, they answered that the area of surface contamination was small and leakage was small. Moreover, the reply that the middle-high part fit the small labia both when dry and when wet was obtained. Also, the absorbent article No. Similarly, when 1-2 was worn by a plurality of subjects, the absorbent article no. Surface contamination than 1-1 responses were obtained with the least and leakage also did.
- Example 2 [Other blood modifying agent data] A commercially available sanitary napkin was prepared.
- the sanitary napkin includes a top sheet formed from an air-through nonwoven fabric (composite fiber made of polyester and polyethylene terephthalate, basis weight: 35 g / m 2 ) treated with a hydrophilic agent, and an air-through nonwoven fabric (composite made of polyester and polyethylene terephthalate).
- Second sheet formed from fibers, basis weight: 30 g / m 2 ), pulp (basis weight: 150 to 450 g / m 2 , more in the center), acrylic superabsorbent polymer (basis weight: 15 g / m 2 ) And an absorbent body containing a tissue as a core wrap, a side sheet treated with a water repellent, and a back sheet made of a polyethylene film.
- Tri-C2L oil fatty acid glyceride manufactured by NOF Corporation C 8 fatty acid: C 10 fatty acid: C 12 fatty acid containing approximately 37: 7: 56 weight ratio, glycerol and fatty acid triester, Weight average molecular weight: about 570
- fatty acids manufactured by NOF Corporation C 8 fatty to C 10 are contained in approximately 85:15 weight ratio of triesters of glycerol with fatty acids, the weight average molecular weight: about 480 ⁇ Panasate 800, manufactured by NOF Corporation All fatty acids are octanoic acid (C 8 ), triester of glycerin and fatty acid, weight average molecular weight: about 470
- Panaceate 800B manufactured by NOF Corporation All fatty acids are 2-ethylhexanoic acid (C 8 ), triester of glycerin and fatty acid, weight average molecular weight: about 470 ⁇ NA36, manufactured by NOF Corporation C 16 fatty acid: fatty acid C 18: (including both saturated and unsaturated fatty acids) fatty acids to C 20 is approximately 5: contained in a weight ratio of 3: 92 triesters of glycerin and fatty acid, the weight average molecular weight: about 880
- C 8 fatty C 10: fatty acid
- C 12 fatty acid
- C 14 (including both saturated and unsaturated fatty acids)
- C 16 is approximately 4 : Triester of glycerin and fatty acid, contained in a weight ratio of 8: 60: 25: 3, weight average molecular weight: 670 -Caprylic acid diglyceride, manufactured by NOF Corporation
- Fatty acid is octanoic acid, diester of glycerin and fatty acid, weight average molecular weight: 340
- Uniol PB1000R polybutylene glycol manufactured by NOF Corporation, weight average molecular weight: about 1000 [(E 2 ) ester of polyoxy C 2 -C 6 alkylene glycol and at least one fatty acid] -Wilbright cp9, manufactured by NOF Co., Ltd.
- Uniol TG-3000 manufactured by NOF Corporation Polyglycol glycol glyceryl ether, about 16 repeating units, weight average molecular weight: about 3,000 ⁇ Uniol TG-4000, glyceryl ether of polypropylene glycol manufactured by NOF Corporation, about 16 repeating units, weight average molecular weight: about 4,000
- [Other materials] -NA50 manufactured by NOF Corporation Hydrogen added to NA36 to reduce the ratio of double bonds derived from the unsaturated fatty acid as a raw material Triester of glycerin and fatty acid, weight average molecular weight: about 880
- PEG 1500 manufactured by NOF Corporation, polyethylene glycol, weight average molecular weight: about 1,500 to about 1,600 Nonionic S-6, polyoxyethylene monostearate manufactured by NOF Corporation, about 7 repeating units, weight average molecular weight: about 880 -Wilbright s753, NOF Corporation polyoxyethylene polyoxypropylene polyoxybutylene glycerin, weight average molecular weight: about 960
- the IOB, melting point and water solubility of the sample are shown in Table 2 below.
- the water solubility was measured according to the method described above, but 20.0 g was added to 100 g of demineralized water, and the sample dissolved after 24 hours was evaluated as “20 g ⁇ ”. Samples that dissolved 0.05 g but did not dissolve 1.00 g were evaluated as 0.05 to 1.00 g.
- “ ⁇ 45” means that the melting point is less than 45 ° C.
- the skin contact surface of the top sheet of the sanitary napkin was coated with the blood modifying agent described above.
- Each blood modifying agent is heated as it is if the blood modifying agent is liquid at room temperature, and if the blood modifying agent is solid at room temperature, it is heated to melting point + 20 ° C., and then control seam HMA gun
- Each blood modifying agent was atomized and applied to the entire skin contact surface of the top sheet so that the basis weight was approximately 5 g / m 2 .
- FIG. 7 is an electron micrograph of the skin contact surface of the top sheet in a sanitary napkin (No. 2-5) in which the top sheet contains tri-C2L oil fatty acid glycerides. As is apparent from FIG. 7, the tri-C2L oil fatty acid glyceride is in the form of fine particles and is attached to the fiber surface. According to the above-mentioned procedure, the rewetting rate and the absorber transfer speed were measured. The results are shown in Table 2 below.
- absorption body transfer rate which is the time for blood to transfer from the top sheet to the absorber, was measured after the second drop of blood.
- absorption body transfer speed means the time from when blood is introduced into the top sheet until the redness of blood is not seen on the surface and inside of the top sheet.
- the rewetting rate was 22.7% and the absorber transfer rate was more than 60 seconds, but all triesters of glycerin and fatty acids had a rewetting rate. Since it is 7.0% or less and the absorber transfer speed is 8 seconds or less, it can be seen that the absorption performance is greatly improved. However, among the triesters of glycerin and fatty acid, NA50 having a melting point exceeding 45 ° C. did not significantly improve the absorption performance.
- a blood modifying agent having an IOB of about 0.00 to about 0.60, a melting point of about 45 ° C. or less, and a water solubility of about 0.00 to about 0.05 g for 100 g of water at 25 ° C. It was found that the absorption performance was greatly improved.
- Example 2 is an example in which the sanitary napkin does not have a predetermined middle-high portion.
- No. 2-32 sanitary napkin is No. 2 containing panacet 810s. Since a result equivalent to 2-7 was obtained, no. 2-1.
- the blood modifying agent used in the sanitary napkin No. 2-32 was used as the absorbent article No. 1 manufactured in Example 1. In the case of application to 1-1, the absorbent article no. It is considered that a result equivalent to 1-2 is obtained.
- Example 3 The rewetting rate was evaluated according to the procedure described above for various animal blood.
- the blood used in the experiment is as follows. [Animal species] (1) Human (2) Horse (3) Sheep
- Defibrinated blood After collecting blood, stirred for about 5 minutes in an Erlenmeyer flask with glass beads
- ⁇ EDTA blood 65 mL of venous blood plus 0.5 mL of 12% EDTA / 2K physiological saline
- Serum or plasma supernatant after centrifuging defibrinated blood or EDTA blood, respectively, at room temperature at about 1900 G for 10 minutes.
- Blood cell serum is removed from the blood, and the residue is phosphate buffered saline (PBS ) Washed twice and then added with phosphate buffered saline for the removed serum
- An absorbent article was produced in the same manner as in Example 2 except that the tri-C2L oil fatty acid glyceride was applied so that the basis weight was approximately 5 g / m 2, and the rewetting rate was evaluated for the various blood types described above. . The measurement was performed 3 times for each blood, and the average value was adopted. The results are shown in Table 3 below.
- Example 2 The same tendency as the horse EDTA blood obtained in Example 2 was also obtained in human and sheep blood. Similar trends were also observed in defibrinated blood and EDTA blood.
- Tri C2L oil fatty acid glyceride is applied to the skin contact surface of the top sheet formed from an air-through nonwoven fabric (a composite fiber composed of polyester and polyethylene terephthalate, basis weight: 35 g / m 2 ) using a control seam HMA gun. It is atomized and applied so that the basis weight is approximately 5 g / m 2 . Moreover, the thing which has not apply
- the weight of the top sheet containing cell strainer + horse EDTA blood: c (g) is measured.
- the post-test absorption amount (g) per 1 g of the top sheet is calculated according to the following formula.
- Absorption after test (g) [c (g) -a (g)] / 0.2 (g) (9)
- the measurement was performed 3 times and the average value was employ
- the top sheet containing a blood modifying agent has low blood retention and can be quickly transferred to an absorber after absorbing blood.
- Example 5 [Viscosity of blood containing blood modifying agents] The viscosity of blood containing a blood modifying agent was measured using Rheometric Expansion System ARES (Rheometric Scientific, Inc). 2% by mass of panacet 810s was added to equine defibrinated blood, lightly stirred to form a sample, the sample was placed on a parallel plate with a diameter of 50 mm, the gap was 100 ⁇ m, and the viscosity was measured at 37 ⁇ 0.5 ° C. . Because of the parallel plate, the sample did not have a uniform shear rate, but the average shear rate displayed on the instrument was 10 s ⁇ 1 .
- the viscosity of equine defibrinated blood containing 2% by mass of panacet 810s was 5.9 mPa ⁇ s, while the viscosity of equine defibrinated blood containing no blood modifying agent was 50.4 mPa ⁇ s. Therefore, it can be seen that equine defibrinated blood containing 2% by mass of panacet 810s decreases the viscosity by about 90% compared to the case where no blood modifying agent is contained.
- blood is known to contain components such as blood cells and have thixotropic properties
- the blood modifying agent of the present disclosure is considered to be able to lower the viscosity of blood in a low viscosity range. It is considered that the absorbed menstrual blood can be quickly transferred from the top sheet to the absorber by lowering the viscosity of the blood.
- Example 6 [Micrograph of blood containing blood modifying agent] A healthy volunteer's menstrual blood is collected on a food protective wrap film, and a portion of the panacet 810s dispersed in 10 times the mass of phosphate buffered saline is used, and the concentration of panacet 810s is 1% by mass.
- Menstrual blood was appropriately applied to a slide glass, covered with a cover glass, and the state of red blood cells was observed with an optical microscope.
- a photomicrograph of menstrual blood containing no blood modifying agent is shown in FIG. 8 (a)
- a photomicrograph of menstrual blood containing panacet 810s is shown in FIG. 8 (b).
- FIG. 8 shows that in menstrual blood that does not contain a blood modifying agent, red blood cells form a collective mass such as remuneration, but in menstrual blood that includes panacet 810s, the red blood cells are each stably dispersed. I understand. Therefore, it is suggested that the blood modifying agent functions to stabilize red blood cells in the blood.
- Example 7 [Surface tension of blood containing blood modifying agents]
- the surface tension of blood containing a blood modifying agent was measured by a pendant drop method using a contact angle meter Drop Master 500 manufactured by Kyowa Interface Science Co., Ltd.
- the surface tension was measured after adding a predetermined amount of blood modifying agent to sheep defibrinated blood and shaking sufficiently. Although the measurement is automatically performed by the instrument, the surface tension ⁇ is obtained by the following equation (see FIG. 9).
- the density ⁇ is defined in 5. of “Density Test Method and Density / Mass / Capacity Conversion Table” of JIS K 2249-1995. Based on the vibration density test method, the temperature was measured as shown in Table 5 below. For measurement, DA-505 of Kyoto Electronics Industry Co., Ltd. was used. The results are shown in Table 5.
- the blood modifying agent has a water solubility of about 0.00 to about 0.05 g in 100 g of water at 25 ° C., but the solubility in water is very low. It can be seen that the surface tension of blood can be lowered. By reducing the surface tension of the blood, it is considered that the absorbed blood can be quickly transferred to the absorbent body without being held between the fibers of the top sheet.
- An absorbent article comprising a liquid-permeable top sheet, a liquid-impermeable back sheet, and an absorbent body between the liquid-permeable top sheet and the liquid-impermeable back sheet,
- the absorbent article has a middle-high portion protruding in the thickness direction of the absorbent article in the excretory opening contact area,
- the middle-high part includes a part of the top sheet and a cushion part disposed between the top sheet and the absorbent body
- the middle-high portion has a central portion and an outer peripheral portion surrounding the central portion, and the density of the cushion portion in the outer peripheral portion is higher than the density of the cushion portion in the central portion,
- the middle-high portion further includes a blood modifying agent having an IOB of 0.00 to 0.60, a melting point of 45 ° C. or lower, and a water solubility of 0.00 to 0.05 g with respect to 100 g of water at 25 ° C.
- the blood modifying agent comprises the following (i) to (iii): (I) hydrocarbons, (Ii) from (ii-1) a hydrocarbon moiety and (ii-2) a carbonyl group (—CO—) and an oxy group (—O—) inserted between the CC single bonds of the hydrocarbon moiety.
- —COOH carboxyl group
- —OH hydroxyl group
- the blood modifying agent comprises the following (i ′) to (iii ′), (I ′) hydrocarbon, (Ii ′) (ii′-1) a hydrocarbon moiety and (ii′-2) a carbonyl bond (—CO—), an ester bond (—COO) inserted between the C—C single bonds of the hydrocarbon moiety.
- the blood modifying agent comprises the following (A) to (F), (A) (A1) a compound having a chain hydrocarbon moiety and 2 to 4 hydroxyl groups replacing hydrogen atoms in the chain hydrocarbon moiety, (A2) a chain hydrocarbon moiety, and the chain An ester with a compound having one carboxyl group for substituting a hydrogen atom in the hydrocarbon moiety, (B) (B1) a compound having a chain hydrocarbon moiety and 2 to 4 hydroxyl groups replacing hydrogen atoms in the chain hydrocarbon moiety, (B2) a chain hydrocarbon moiety, and the chain An ether with a compound having one hydroxyl group replacing a hydrogen atom of the hydrocarbon moiety, (C) (C1) a carboxylic acid, a hydroxy acid, an alkoxy acid or an oxo acid containing a chain hydrocarbon moiety and 2 to 4 carboxyl groups replacing a hydrogen atom in the chain hydrocarbon moiety; C2) an ester of a compound having a chain hydrocarbon
- the blood modifying agent comprises (a 1 ) an ester of a chain hydrocarbon tetraol and at least one fatty acid, (a 2 ) an ester of a chain hydrocarbon triol and at least one fatty acid, (a 3 ) a chain An ester of a hydrocarbon diol and at least one fatty acid, (b 1 ) an ether of a chain hydrocarbon tetraol and at least one aliphatic monohydric alcohol, (b 2 ) a chain hydrocarbon triol and at least one aliphatic Ethers with monohydric alcohols, (b 3 ) ethers of chain hydrocarbon diols with at least one aliphatic monohydric alcohol, (c 1 ) chain hydrocarbon tetracarboxylic acids having 4 carboxyl groups, hydroxy acids , alkoxy acid or an oxo acid, at least one ester of an aliphatic monohydric alcohol, (c 2) a chain hydrocarbon tricaprate with 3 carboxyl
- Aspect 14 The absorbent article according to any one of aspects 1 to 13, which is a sanitary napkin or a panty liner.
Landscapes
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Materials Engineering (AREA)
- Physics & Mathematics (AREA)
- Fluid Mechanics (AREA)
- Manufacturing & Machinery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Absorbent Articles And Supports Therefor (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
Abstract
Description
従って、本開示は、経血を吸収する前のドライ時と、経血を吸収した後のウェット時との両方において、着用者の排泄口、特に、小陰唇にフィットし、漏れを生じさせにくい吸収性物品を提供することを目的とする。
図1は、本開示の実施形態の1つに従う吸収性物品の斜視図である。図1に示される吸収性物品1は、生理用ナプキンである。図1に示される吸収性物品1では、向かって右奥が着用者の前方に相当し、そして向かって左手前が着用者の後方に相当するが、図1に示される吸収性物品1は、おおむね、前後対称且つ左右対称の形状を有する。
なお、図1に示される吸収性物品1では、トップシート5が、肌当接面に、長手方向に延びる、複数の畝溝構造を有しており、図1では、便宜上、畝と溝との境界が、実線で示されている。図1に示される吸収性物品1では、2本の実線で囲まれた幅の広い領域が畝部を意味し、そして2本の実線で囲まれた幅の狭い領域が溝部を意味し、図1に示される吸収性物品1では、複数の畝部と、複数の溝部とが、吸収性物品1の幅方向に交互に配置されている。図1にはまた、中高部2を囲む周囲部3が示されている。
また、本明細書において、「中高部」は、トップシートと、クッション部とを含む部分を意味し、そして概ね、吸収性物品の最大厚さを有する点から、外周部に向かってその厚さが薄くなる。
また、中高部に関する「中央部」は、上記厚さが最も厚い点から、中高部の外縁までの距離の、好ましくは0~約50%、より好ましくは0~約40%、そしてさらに好ましくは0~約30%の領域を意味する。
上記繊維含有物としては、例えば、天然繊維、化学繊維、又はそれらの両方を含むものが挙げられ、複数の繊維の交点が熱融着されているものが好ましい。繊維の交点が熱融着されることにより、経血を吸収した後であっても、クッション部、ひいては中高部が形状安定性に優れることができる。
上記繊維含有物は、繊維同士を熱融着させるために、熱可塑性化学繊維を、好ましくは約50~約100質量%、そしてより好ましくは約70~約100質量%含む。
上記クッション部が繊維含有物である場合には、繊維含有物を構成する繊維としては、圧縮回復性を考慮すると、単繊維よりも複合繊維が好ましく、鞘部にポリエチレンを含む芯鞘型繊維であることがより好ましい。
上記クッション部が繊維含有物である場合には、クッション部を構成する繊維は、経血等の入り込みやすさ、肌触り等を考慮すると、約1.1~約8.8dtexの繊度を有することが好ましい。
なお、上記連続発泡体は、発泡セルが開孔している、開孔型発泡体を意味する。発泡セルが開孔していない、閉孔型発泡体は、クッション部の内部を、経血が通過しにくく、液透過性に劣る。
また、トップシートが膣口と緻密に接触できるため、着用中は、膣口と、吸収体との距離が近く、クッション部が主に熱可塑性化学繊維から構成されている場合には、最初の経血の吸収時において、経血を平面方向に拡散させることなく、トップシート及びクッション部を通過して、吸収体に迅速に移行させることができる。一度経血の通り道ができると、その領域は親水化されるため、2回目以降の経血の吸収の際にも、経血は、トップシート及びクッション部を通過して、迅速に吸収体に移行することができる。
なお、クッション部に関する「中心」は、吸収性物品の長手方向及び幅方向の中心を意味する。
さらに、上記クッション部は、その坪量が場所によって異なっていてもよい。
(1)2次元レーザー変位計を用いて、測定すべき位置のクッション部の厚さt(cm)を測定する。上記2次元レーザー変位計としては、例えば、キーエンス株式会社製 高精度2次元レーザー変位計 LJ-Gシリーズ(型式:LJ-G030)が挙げられる。なお、測定すべき位置のクッション部の厚さは、測定すべき位置の吸収性物品の厚さから、クッション部の存在しない領域、すなわち、中高部を囲む周囲部における吸収性物品の厚さを減ずることにより算出することができる。
(3)密度d(g/cm3)を、下記式:
d=b/(10,000×t)
に従って算出する。
なお、本明細書において、クッション部及び中高部に関する「最大厚さ」は、それぞれ、クッション部及び中高部のうち、最も厚い部分の厚さを意味する。
なお、ウマEDTA血2gを吸収させた後のクッション部の最大厚さは、ウマEDTA血を全て吸収させてから1分経過後に測定することができる。また、クッション部の最大厚さは、上述の2次元レーザー変位計を用いて測定することができる。
なお、EDTA血については、後述する。
本発明のさらに別の実施形態に従う吸収性物品では、液透過性のトップシートが、複数のピン開孔部を有する。
また、本開示の吸収性物品は、着用者の排泄口、特に、小陰唇にフィットし、漏れを生じさせにくいため、そのサイズを小さくすることができ、本開示の吸収性物品は、好ましくは約100~約500mm、より好ましくは約120~約350mm、そしてさらに好ましくは約150~約250mmの長手方向の長さと、好ましくは約40~約200mm、より好ましくは約45~約180mm、そしてさらに好ましくは約50~100mmの幅方向の長さとを有する。
IOB(Inorganic Organic Balance)は、親水性及び親油性のバランスを示す指標であり、本明細書では、小田らによる次式:
IOB=無機性値/有機性値
により算出される値を意味する。
藤田氏による、主要な基の有機性値及び無機性値を、下記表1にまとめる。
本開示の吸収性物品が、人体に接して用いられることを考慮すると、上記蒸気圧は、40℃(1気圧)で約0~約700Paであることが好ましく、約0~約100Paであることがより好ましく、そして約0~約10Paであることがさらに好ましく、約0~約1Paであることがさらにいっそう好ましく、そして約0.0~約0.1Paであることがさらにいっそう好ましい。蒸気圧が高いと、保存中に気化し、血液改質剤の量の減少、着用時の臭気等の問題が発生する場合があるからである。
また、吸収性物品が長時間にわたって使用される場合には、血液改質剤の融点は、45℃以下の範囲で高い方が好ましい。汗、着用時の摩擦等の影響を受けにくく、長時間着用した場合であっても、血液改質剤が移動しにくいからである。
なお、本明細書では、水溶解度に関して、「溶解」には、試料が脱イオン水に完全に溶解し、均一混合物を形成した場合と、試料が完全にエマルション化した場合とが含まれる。なお、「完全」とは、脱イオン水に、試料の塊が存在しないことを意味する。
Mw=ΣNiMi 2/ΣNiMi
により求められるMwを意味する。
GPCの測定条件としては、例えば、以下が挙げられる。
機種:(株)日立ハイテクノロジーズ製 高速液体クロマトグラム Lachrom Elite
カラム:昭和電工(株)製 SHODEX KF-801、KF-803及びKF-804
溶離液:THF
流量 :1.0mL/分
打込み量:100μL
検出:RI(示差屈折計)
なお、本明細書の実施例に記載される重量平均分子量は、上記条件により測定したものである。
(i)炭化水素、
(ii) (ii-1)炭化水素部分と、(ii-2)上記炭化水素部分のC-C単結合間に挿入された、カルボニル基(-CO-)及びオキシ基(-O-)から成る群から選択される、一又は複数の、同一又は異なる基とを有する化合物、及び
(iii) (iii-1)炭化水素部分と、(iii-2)上記炭化水素部分のC-C単結合間に挿入された、カルボニル基(-CO-)及びオキシ基(-O-)から成る群から選択される、一又は複数の、同一又は異なる基と、(iii-3)上記炭化水素部分の水素原子を置換する、カルボキシル基(-COOH)及びヒドロキシル基(-OH)から成る群から選択される、一又は複数の、同一又は異なる基とを有する化合物、
並びにそれらの任意の組み合わせから成る群から選択される。
上記鎖状炭化水素には、直鎖状炭化水素及び分岐鎖状炭化水素が含まれる。
(i’)炭化水素、
(ii’) (ii’-1)炭化水素部分と、(ii’-2)上記炭化水素部分のC-C単結合間に挿入された、カルボニル結合(-CO-)、エステル結合(-COO-)、カーボネート結合(-OCOO-)、及びエーテル結合(-O-)から成る群から選択される、一又は複数の、同一又は異なる結合とを有する化合物、及び
(iii’) (iii’-1)炭化水素部分と、(iii’-2)上記炭化水素部分のC-C単結合間に挿入された、カルボニル結合(-CO-)、エステル結合(-COO-)、カーボネート結合(-OCOO-)、及びエーテル結合(-O-)から成る群から選択される、一又は複数の、同一又は異なる結合と、(iii’-3)上記炭化水素部分の水素原子を置換する、カルボキシル基(-COOH)及びヒドロキシル基(-OH)から成る群から選択される、一又は複数の、同一又は異なる基とを有する化合物、
並びにそれらの任意の組み合わせから成る群から選択される。
(A) (A1)鎖状炭化水素部分と、上記鎖状炭化水素部分の水素原子を置換する2~4個のヒドロキシル基とを有する化合物と、(A2)鎖状炭化水素部分と、上記鎖状炭化水素部分の水素原子を置換する1個のカルボキシル基とを有する化合物とのエステル、
(B) (B1)鎖状炭化水素部分と、上記鎖状炭化水素部分の水素原子を置換する2~4個のヒドロキシル基とを有する化合物と、(B2)鎖状炭化水素部分と、上記鎖状炭化水素部分の水素原子を置換する1個のヒドロキシル基とを有する化合物とのエーテル、
(C) (C1)鎖状炭化水素部分と、上記鎖状炭化水素部分の水素原子を置換する、2~4個のカルボキシル基とを含むカルボン酸、ヒドロキシ酸、アルコキシ酸又はオキソ酸と、(C2)鎖状炭化水素部分と、上記鎖状炭化水素部分の水素原子を置換する1個のヒドロキシル基とを有する化合物とのエステル、
(D)鎖状炭化水素部分と、上記鎖状炭化水素部分のC-C単結合間に挿入された、エーテル結合(-O-)、カルボニル結合(-CO-)、エステル結合(-COO-)、及びカーボネート結合(-OCOO-)から成る群から選択されるいずれか1つの結合とを有する化合物、
(E)ポリオキシC2~C6アルキレングリコール、又はそのアルキルエステル若しくはアルキルエーテル、及び
(F)鎖状炭化水素、
並びにそれらの任意の組み合わせから成る群から選択される。
以下、(A)~(F)に従う血液改質剤について詳細に説明する。
(A) (A1)鎖状炭化水素部分と、上記鎖状炭化水素部分の水素原子を置換する2~4個のヒドロキシル基とを有する化合物と、(A2)鎖状炭化水素部分と、上記鎖状炭化水素部分の水素原子を置換する1個のカルボキシル基とを有する化合物とのエステル(以下、「化合物(A)」と称する場合がある)は、上述のIOB、融点及び水溶解度を有する限り、全てのヒドロキシル基がエステル化されていなくともよい。
(A2)鎖状炭化水素部分と、上記鎖状炭化水素部分の水素原子を置換する1個のカルボキシル基とを有する化合物(以下、「化合物(A2)」と称する場合がある)としては、例えば、炭化水素上の1つの水素原子が、1つのカルボキシル基(-COOH)で置換された化合物、例えば、脂肪酸が挙げられる。
化合物(A)としては、例えば、(a1)鎖状炭化水素テトラオールと少なくとも1の脂肪酸とのエステル、(a2)鎖状炭化水素トリオールと少なくとも1の脂肪酸とのエステル、及び(a3)鎖状炭化水素ジオールと少なくとも1の脂肪酸とのエステルが挙げられる。
上記鎖状炭化水素テトラオールと少なくとも1の脂肪酸とのエステルとしては、例えば、次の式(1):
(式中、R1~R4は、それぞれ、鎖状炭化水素である)
また、上記ペンタエリトリトールと脂肪酸とのエステルとしては、IOBを小さくし、より疎水性とするために、ジエステル、トリエステル又はテトラエステルであることが好ましく、トリエステル又はテトラエステルであることがより好ましく、そしてテトラエステルであることがさらに好ましい。
上記ペンタエリトリトールと脂肪酸とのテトラエステルでは、例えば、ペンタエリトリトールと、ヘキサン酸(C6)、ヘプタン酸(C7)、オクタン酸(C8)、例えば、2-エチルヘキサン酸(C8)、ノナン酸(C9)、デカン酸(C10)及び/又はドデカン酸(C12)とのテトラエステルが挙げられる。
なお、上記計算に当たっては、二重結合、三重結合、iso分岐、及びtert分岐の影響は、考慮していない。
上記鎖状炭化水素トリオールと少なくとも1の脂肪酸とのエステルとしては、例えば、次の式(5):
のグリセリンと脂肪酸とのモノエステルが挙げられる。
上記グリセリンと脂肪酸とのトリエステルは、いわゆる、脂肪であり、人体を構成しうる成分であるため、安全性の観点から好ましい。
上記グリセリンと脂肪酸とのモノエステルでは、グリセリンと脂肪酸とのモノエステルを構成する脂肪酸の炭素数、すなわち、式(7)において、R5C部分の炭素数が19の場合にIOBが0.59となる。従って、上記グリセリンと脂肪酸とのモノエステルを構成する脂肪酸の炭素数が約19以上である場合に、IOBが約0.00~約0.60の要件を満たす。
上記鎖状炭化水素ジオールと少なくとも1の脂肪酸とのエステルとしては、例えば、C2~C6の鎖状炭化水素ジオール、例えば、C2~C6のグリコール、例えば、エチレングリコール、プロピレングリコール、ブチレングリコール、ペンチレングリコール又はヘキシレングリコールと、脂肪酸とのモノエステル又はジエステルが挙げられる。
R8COOCkH2kOCOR9 (8)
(式中、kは、2~6の整数であり、そしてR8及びR9は、それぞれ、鎖状炭化水素である)
のC2~C6グリコールと脂肪酸とのジエステル、及び次の式(9):
R8COOCkH2kOH (9)
(式中、kは、2~6の整数であり、そしてR8は、鎖状炭化水素である)
のC2~C6グリコールと脂肪酸とのモノエステルが挙げられる。
上記C2~C6グリコールと脂肪酸とのエステルの市販品としては、例えば、コムポールBL、コムポールBS(以上、日油株式会社製)等が挙げられる。
(B) (B1)鎖状炭化水素部分と、上記鎖状炭化水素部分の水素原子を置換する2~4個のヒドロキシル基とを有する化合物と、(B2)鎖状炭化水素部分と、上記鎖状炭化水素部分の水素原子を置換する1個のヒドロキシル基とを有する化合物とのエーテル(以下、「化合物(B)」と称する場合がある)は、上述のIOB、融点及び水溶解度を有する限り、全てのヒドロキシル基がエーテル化されていなくともよい。
(B2)鎖状炭化水素部分と、上記鎖状炭化水素部分の水素原子を置換する1個のヒドロキシル基とを有する化合物(以下、「化合物(B2)」と称する場合がある)としては、例えば、炭化水素の1個の水素原子が、1個のヒドロキシル基(-OH)で置換された化合物、例えば、脂肪族1価アルコール、例えば、飽和脂肪族1価アルコール及び不飽和脂肪族1価アルコールが挙げられる。
の、ペンタエリトリトールと脂肪族1価アルコールとのテトラエーテル、トリエーテル、ジエーテル及びモノエーテルが挙げられる。
の、グリセリンと脂肪族1価アルコールとのトリエーテル、ジエーテル及びモノエーテルが挙げられる。
R17OCnH2nOR18 (17)
(式中、nは、2~6の整数であり、そしてR17及びR18は、それぞれ、鎖状炭化水素である)
のC2~C6グリコールと脂肪族1価アルコールとのジエーテル、及び次の式(18):
R17OCnH2nOH (18)
(式中、nは、2~6の整数であり、そしてR17は、鎖状炭化水素である)
のC2~C6グリコールと脂肪族1価アルコールとのモノエーテルが挙げられる。
(C) (C1)鎖状炭化水素部分と、上記鎖状炭化水素部分の水素原子を置換する、2~4個のカルボキシル基とを含むカルボン酸、ヒドロキシ酸、アルコキシ酸又はオキソ酸と、(C2)鎖状炭化水素部分と、上記鎖状炭化水素部分の水素原子を置換する1個のヒドロキシル基とを有する化合物とのエステル(以下、「化合物(C)」と称する場合がある)は、上述のIOB、融点及び水溶解度を有する限り、全てのカルボキシル基がエステル化されていなくともよい。
(C2)鎖状炭化水素部分と、上記鎖状炭化水素部分の水素原子を置換する1個のヒドロキシル基とを有する化合物としては、「化合物(B)」の項で列挙されるもの、例えば、脂肪族1価アルコールが挙げられる。
化合物(C)の例としては、アジピン酸ジオクチル、O-アセチルクエン酸トリブチル等が挙げられ、そして市販されている。
(D)鎖状炭化水素部分と、上記鎖状炭化水素部分のC-C単結合間に挿入された、エーテル結合(-O-)、カルボニル結合(-CO-)、エステル結合(-COO-)、及びカーボネート結合(-OCOO-)から成る群から選択されるいずれか1つの結合とを有する化合物(以下、「化合物(D)」と称する場合がある)としては、(d1)脂肪族1価アルコールと脂肪族1価アルコールとのエーテル、(d2)ジアルキルケトン、(d3)脂肪酸と脂肪族1価アルコールとのエステル、及び(d4)ジアルキルカーボネートが挙げられる。
上記脂肪族1価アルコールと脂肪族1価アルコールとのエーテルとしては、次の式(19):
R19OR20 (19)
(式中、R19及びR20は、それぞれ、鎖状炭化水素である)
を有する化合物が挙げられる。
上記ジアルキルケトンとしては、次の式(20):
R21COR22 (20)
(式中、R21及びR22は、それぞれ、アルキル基である)
を有する化合物が挙げられる。
なお、上記炭素数の合計が約8の場合、例えば、5-ノナノンでは、融点は約-50℃であり、蒸気圧は20℃で約230Paである。
上記ジアルキルケトンは、市販されている他、公知の方法、例えば、第二級アルコールを、クロム酸等で酸化することにより得ることができる。
上記脂肪酸と脂肪族1価アルコールとのエステルとしては、例えば、次の式(21):
R23COOR24 (21)
(式中、R23及びR24は、それぞれ、鎖状炭化水素である)
を有する化合物が挙げられる。
上記ジアルキルカーボネートとしては、次の式(22):
R25OC(=O)OR26 (22)
(式中、R25及びR26は、それぞれ、アルキル基である)
を有する化合物が挙げられる。
水溶解度を考慮すると、R25及びR26の炭素数の合計が約7以上であることが好ましく、そして約9以上であることがより好ましい。
上記ジアルキルカーボネートは、市販されている他、ホスゲンとアルコールとの反応、塩化ギ酸エステルとアルコール又はアルコラートとの反応、及び炭酸銀とヨウ化アルキルとの反応により合成することができる。
上記ポリオキシC2~C6アルキレングリコール、又はそのエステル若しくはエーテル(以下、化合物(E)と称する場合がある)としては、(e1)ポリオキシC2~C6アルキレングリコール、(e2)ポリオキシC2~C6アルキレングリコールと少なくとも1の脂肪酸とのエステル、(e3)ポリオキシC2~C6アルキレングリコールと少なくとも1の脂肪族1価アルコールとのエーテル、(e4)ポリオキシC2~C6アルキレングリコールと、鎖状炭化水素テトラカルボン酸、鎖状炭化水素トリカルボン酸、又は鎖状炭化水素ジカルボン酸とのエステル、及び(e5)ポリオキシC2~C6アルキレングリコールと、鎖状炭化水素テトラオール、鎖状炭化水素トリオール、又は鎖状炭化水素ジオールとのエーテルが挙げられる。以下、説明する。
上記ポリオキシC2~C6アルキレングリコールは、i)オキシC2~C6アルキレン骨格、すなわち、オキシエチレン骨格、オキシプロピレン骨格、オキシブチレン骨格、オキシペンチレン骨格、及びオキシヘキシレン骨格から成る群から選択されるいずれか1種の骨格を有し且つ両末端にヒドロキシ基を有するホモポリマー、ii)上記群から選択される2種以上の骨格を有し且つ両末端にヒドロキシ基を有するブロックコポリマー、又はiii)上記群から選択される2種以上の骨格を有し且つ両末端にヒドロキシ基を有するランダムコポリマーを意味する。
HO-(CmH2mO)n-H (23)
(式中、mは2~6の整数である)
により表わされうる。
以上より、式(23)において、mは、約3~約6であり、そして約4~約6であることがより好ましく、そしてnは2以上である。
例えば、式(23)がポリプロピレングリコール(m=3のホモポリマー)である場合には、n=12の場合に、IOBが0.58となる。従って、式(23)がポリプロピレングリコール(m=3のホモポリマー)である場合には、m≧約12の場合に、上記IOBの要件を満たす。
また、式(23)がポリブチレングリコール(m=4のホモポリマー)である場合には、n=7の場合に、IOBが0.57となる。従って、式(23)がポリブチレングリコール(m=4のホモポリマー)である場合には、n≧約7の場合に、上記IOBの要件を満たす。
また、IOB、融点及び水溶解度の観点から、ポリオキシC3アルキレングリコール、すなわち、ポリプロピレングリコールの重量平均分子量は、好ましくは約1,000~約10,000、より好ましくは約3,000~約8,000、そしてさらに好ましくは、約4,000~約5,000の範囲にある。上記重量平均分子量が約1,000未満では、水溶解度が要件を満たさず、そして重量平均分子量が大きいほど、特に、吸収体移行速度及びトップシートの白さが向上する傾向があるからである。
上記ポリオキシC2~C6アルキレングリコールと少なくとも1の脂肪酸とのエステルとしては、「(e1)ポリオキシC2~C6アルキレングリコール」の項で説明したポリオキシC2~C6アルキレングリコールのOH末端の一方又は両方が、脂肪酸によりエステル化されているもの、すなわち、モノエステル及びジエステルが挙げられる。
上記ポリオキシC2~C6アルキレングリコールと脂肪酸とのエステルの市販品としては、例えば、ウィルブライトcp9(日油株式会社製)が挙げられる。
上記ポリオキシC2~C6アルキレングリコールと少なくとも1の脂肪族1価アルコールとのエーテルとしては、「(e1)ポリオキシC2~C6アルキレングリコール」の項で説明したポリオキシC2~C6アルキレングリコールのOH末端の一方又は両方が、脂肪族1価アルコールによりエーテル化されているもの、すなわち、モノエーテル及びジエーテルが挙げられる。
ポリオキシC2~C6アルキレングリコールと少なくとも1の脂肪族1価アルコールとのエーテルにおいて、エーテル化すべき脂肪族1価アルコールとしては、例えば、「化合物(B)」の項で列挙されている脂肪族1価アルコールが挙げられる。
上記ポリオキシC2~C6アルキレングリコールと、鎖状炭化水素テトラカルボン酸、鎖状炭化水素トリカルボン酸、又は鎖状炭化水素ジカルボン酸とのエステルにおいて、エステル化すべきポリオキシC2~C6アルキレングリコールとしては、「(e1)ポリオキシC2~C6アルキレングリコール」の項で説明したポリオキシC2~C6アルキレングリコールが挙げられる。また、エステル化すべき鎖状炭化水素テトラカルボン酸、鎖状炭化水素トリカルボン酸、及び鎖状炭化水素ジカルボン酸としては、「化合物(C)」の項で説明されるものが挙げられる。
上記ポリオキシC2~C6アルキレングリコールと、鎖状炭化水素テトラオール、鎖状炭化水素トリオール、又は鎖状炭化水素ジオールとのエーテルにおいて、エーテル化すべきポリオキシC2~C6アルキレングリコールとしては、「(e1)ポリオキシC2~C6アルキレングリコール」の項で説明したポリオキシC2~C6アルキレングリコールが挙げられる。また、エーテル化すべき鎖状炭化水素テトラオール、鎖状炭化水素トリオール、及び鎖状炭化水素ジオールとしては、「化合物(A)」の項で説明されるもの、例えば、ペンタエリトリトール、グリセリン、及びグリコールが挙げられる。
ユニルーブ(商標)5TP-300KBは、ペンタエリトリトール1モルに、プロピレングリコール65モルと、エチレングリコール5モルとを重縮合させた化合物であり、そのIOBは0.39であり、融点は45℃未満であり、そして水溶解度は0.05g未満であった。
ユニオール(商標)TG-4000は、グリセリン1モルに、プロピレングリコール70モルを重縮合させた化合物であり、そのIOBは0.40であり、融点は45℃未満であり、水溶解度は0.05g未満であり、そして重量平均分子量は約4,000であった。
上記鎖状炭化水素は、上記無機性値が0であることから、IOBが0.00であり、そして水溶解度がほぼ0gであるので、融点が約45℃以下のものであれば、上記血液改質剤に含まれうる。上記鎖状炭化水素としては、例えば、(f1)鎖状アルカン、例えば、直鎖アルカン及び分岐鎖アルカンが挙げられ、例えば、直鎖アルカンの場合には、融点が約45℃以下であることを考慮すると、おおむね、炭素数が22以下のものが含まれる。また、蒸気圧を考慮すると、おおむね、炭素数が13以上のものが含まれる。分岐鎖アルカンの場合には、直鎖アルカンよりも、同一炭素数において、融点が低くなる場合があるため、炭素数が22以上のものも含まれうる。
上記炭化水素の市販品としては、例えば、パールリーム6(日油株式会社)が挙げられる。
上記改質剤が、血球を安定化させ、血球に連銭構造を形成しにくくすることにより、吸収体が経血を吸収しやすくなると考えられる。例えば、アクリル系高吸収ポリマー、いわゆる、SAPを含む吸収性物品では、経血を吸収すると、連銭した血球がSAP表面を覆い、SAPが吸収性能を発揮しにくくなることが知られているが、血球を安定化することにより、SAPが吸収性能を発揮しやすくなると考えられる。また、赤血球と親和性の高い血液改質剤が、赤血球膜を保護するため、赤血球が破壊されにくくなると考えられる。
上記不織布の例としては、例えば、エアスルー不織布、スパンボンド不織布、ポイントボンド不織布、スパンレース不織布、ニードルパンチ不織布、メルトブローン不織布、及びこれらの組み合わせ(例えば、SMS等)等が挙げられる。
上記吸収コアの構成要素としては、例えば、親水性繊維、例えば、粉砕パルプ、コットン等のセルロース、レーヨン、フィブリルレーヨン等の再生セルロース、アセテート、トリアセテート等の半合成セルロース、粒子状ポリマー、繊維状ポリマー、熱可塑性疎水性化学繊維、及び親水化処理された熱可塑性疎水性化学繊維、並びにこれらの組み合わせ等が挙げられる。また、上記吸収コアの構成要素として、高吸収性ポリマー、例えば、アクリル酸ナトリウムコポリマー等の粒状物が挙げられる。
また、上記血液改質剤は、トップシートの平面方向に関しては、トップシートの全面、膣口付近の中心領域等、任意の場所に存在することができる。
また、中高部が上記血液改質剤を含む実施形態において、上記血液改質剤は、吸収した血液に迅速に移行するために、その表面積が大きいことが好ましく、液滴状又は粒子状で存在する血液改質剤は、粒径が小さいことが好ましい。
[製造例1]
トップシートとして、ポリエチレン(PE)の鞘と、ポリエチレンテレフタレート(PET)の芯とから形成された芯鞘構造を有し、親水処理された複合繊維(繊度:2.8dtexの)から成るエアスルー不織布(坪量:30g/m2)を準備した。
パルプ及びSAPを、90:10(質量比)でブレンドした混合物(坪量:250g/m2)を、ティッシュ(坪量:14g/m2)で巻くことにより、吸収体を形成した。バックシートとして、PEを含むフィルム(坪量:23g/m2)の片面に、接着剤が塗布されたものを準備した。
血液改質剤として、パナセート810s(日油株式会社製、グリセリンと脂肪酸とのトリエステル)を選択し、吸収性物品No.1-1の中高部を中心に、室温において、コントロールシームHMAガンから5.0g/m2の坪量で、パナセート810sを塗工することにより、吸収性物品No.1-2を製造した。電子顕微鏡で確認したところ、パナセート810sは、微粒子状で、中高部のトップシートの繊維の表面に付着していた。
吸収性物品No.1-1を10名の被験者に着用してもらったところ、計18回の試験において、表面汚れの面積が少なく、且つ漏れが少ないとの回答を得た。また、ドライ時及びウェット時の両方において、中高部が小陰唇にフィットしていたとの回答を得た。
また、吸収性物品No.1-2を、同様に、複数の被験者に着用してもらったところ、吸収性物品No.1-1よりも表面汚れが少なく且つ漏れもなかったとの回答を得た。
[その他の血液改質剤のデータ]
市販の生理用ナプキンを準備した。当該生理用ナプキンは、親水剤で処理されたエアスルー不織布(ポリエステル及びポリエチレンテレフタレートから成る複合繊維、坪量:35g/m2)から形成されたトップシートと、エアスルー不織布(ポリエステル及びポリエチレンテレフタレートから成る複合繊維、坪量:30g/m2)から形成されたセカンドシートと、パルプ(坪量:150~450g/m2、中央部ほど多い)、アクリル系高吸収ポリマー(坪量:15g/m2)及びコアラップとしてのティッシュを含む吸収体と、撥水剤処理されたサイドシートと、ポリエチレンフィルムから成るバックシートとから形成されていた。
[(a1)鎖状炭化水素テトラオールと少なくとも1の脂肪酸とのエステル]
・ユニスター H-408BRS,日油株式会社製
テトラ2-エチルヘキサン酸ペンタエリトリトール,重量平均分子量:約640
・ユニスター H-2408BRS-22,日油株式会社製
テトラ2-エチルヘキサン酸ペンタエリトリトールと、ジ2-エチルヘキサン酸ネオペンチルグリコールとの混合物(58:42,重量比),重量平均分子量:約520
・Cetiol SB45DEO,コグニスジャパン株式会社製
脂肪酸が、オレイン酸又はステアリル酸である、グリセリンと脂肪酸とのトリエステル
・SOY42,日油株式会社製
C14の脂肪酸:C16の脂肪酸:C18の脂肪酸:C20の脂肪酸(飽和脂肪酸及び不飽和脂肪酸の両方を含む)がおおよそ0.2:11:88:0.8の重量比で含まれている、グリセリンと脂肪酸とのトリエステル,重量平均分子量:880
C8の脂肪酸:C10の脂肪酸:C12の脂肪酸がおおよそ37:7:56の重量比で含まれている、グリセリンと脂肪酸とのトリエステル,重量平均分子量:約570
・トリCL油脂肪酸グリセリド,日油株式会社製
C8の脂肪酸:C12の脂肪酸がおおよそ44:56の重量比で含まれている、グリセリンと脂肪酸とのトリエステル,重量平均分子量:約570
C8の脂肪酸:C10の脂肪酸がおおよそ85:15の重量比で含まれている、グリセリンと脂肪酸とのトリエステル,重量平均分子量:約480
・パナセート800,日油株式会社製
脂肪酸が全てオクタン酸(C8)である、グリセリンと脂肪酸とのトリエステル,重量平均分子量:約470
脂肪酸が全て2-エチルヘキサン酸(C8)である、グリセリンと脂肪酸とのトリエステル,重量平均分子量:約470
・NA36,日油株式会社製
C16の脂肪酸:C18の脂肪酸:C20の脂肪酸(飽和脂肪酸及び不飽和脂肪酸の両方を含む)がおおよそ5:92:3の重量比で含まれている、グリセリンと脂肪酸とのトリエステル,重量平均分子量:約880
C8の脂肪酸:C10の脂肪酸:C12の脂肪酸:C14の脂肪酸:C16の脂肪酸(飽和脂肪酸及び不飽和脂肪酸の両方を含む)がおおよそ4:8:60:25:3の重量比で含まれている、グリセリンと脂肪酸とのトリエステル,重量平均分子量:670
・カプリル酸ジグリセリド,日油株式会社製
脂肪酸がオクタン酸である、グリセリンと脂肪酸とのジエステル,重量平均分子量:340
・コムポールBL,日油株式会社製
ブチレングリコールのドデカン酸(C12)モノエステル,重量平均分子量:約270
・コムポールBS,日油株式会社製
ブチレングリコールのオクタデカン酸(C18)モノエステル,重量平均分子量:約350
・ユニスター H-208BRS,日油株式会社製
ジ2-エチルヘキサン酸ネオペンチルグリコール,重量平均分子量:約360
・O-アセチルクエン酸トリブチル,東京化成工業株式会社製
重量平均分子量:約400
・アジピン酸ジオクチル,和光純薬工業製
重量平均分子量:約380
・エレクトールWE20,日油株式会社製
ドデカン酸(C12)と、ドデシルアルコール(C12)とのエステル,重量平均分子量:約360
・エレクトールWE40,日油株式会社製
テトラデカン酸(C14)と、ドデシルアルコール(C12)とのエステル,重量平均分子量:約390
・ユニオールD-1000,日油株式会社製
ポリプロピレングリコール,重量平均分子量:約1,000
・ユニオールD-1200,日油株式会社製
ポリプロピレングリコール,重量平均分子量:約1,200
・ユニオールD-3000,日油株式会社製
ポリプロピレングリコール,重量平均分子量:約3,000
ポリプロピレングリコール,重量平均分子量:約4,000
・ユニオールPB500,日油株式会社製
ポリブチレングリコール,重量平均分子量:約500
・ユニオールPB700,日油株式会社製
ポリオキシブチレンポリオキシプロピレングリコール,重量平均分子量:約700
ポリブチレングリコール,重量平均分子量:約1000
[(e2)ポリオキシC2~C6アルキレングリコールと少なくとも1の脂肪酸とのエステル]
・ウィルブライトcp9,日油株式会社製
ポリブチレングリコールの両末端のOH基が、ヘキサデカン酸(C16)によりエステル化された化合物,重量平均分子量:約1,150
・ユニルーブMS-70K,日油株式会社製
ポリプロピレングリコールのステアリルエーテル,約15の繰返し単位,重量平均分子量:約1,140
・ユニルーブ5TP-300KB
ペンタエリトリトール1モルに、エチレンオキシド5モルと、プロピレンオキシド65モルとを付加させることにより生成した、ポリオキシエチレンポリオキシプロピレンペンタエリスリトールエーテル,重量平均分子量:4,130
ポリプロピレングリコールのグリセリルエーテル,約16の繰返し単位,重量平均分子量:約3,000
・ユニオール TG-4000,日油株式会社製
ポリプロピレングリコールのグリセリルエーテル,約16の繰返し単位,重量平均分子量:約4,000
・パールリーム6,日油株式会社製
流動イソパラフィン、イソブテン及びn-ブテンを共重合し、次いで水素を付加することにより生成された分岐鎖炭化水素、重合度:約5~約10,重量平均分子量:約330
・NA50,日油株式会社製
NA36に水素を付加し、原料である不飽和脂肪酸に由来する二重結合の比率を下げたグリセリンと脂肪酸とのトリエステル,重量平均分子量:約880
・(カプリル酸/カプリン酸)モノグリセリド,日油株式会社製
オクタン酸(C8)及びデカン酸(C10)がおおよそ85:15の重量比で含まれている、グリセリンと脂肪酸とのモノエステル,重量平均分子量:約220
・Monomuls 90-L2ラウリン酸モノグリセリド,コグニスジャパン株式会社製
重量平均分子量:約230
・リンゴ酸ジイソステアリル
重量平均分子量:約640
・ユニオールD-400,日油株式会社製
ポリプロピレングリコール,重量平均分子量:約400
ポリエチレングリコール,重量平均分子量:約1,500~約1,600
・ノニオンS-6,日油株式会社製
ポリオキシエチレンモノステアレート、約7の繰返し単位、重量平均分子量:約880
・ウィルブライトs753,日油株式会社製
ポリオキシエチレンポリオキシプロピレンポリオキシブチレングリセリン,重量平均分子量:約960
ポリプロピレングリコールのグリセリルエーテル,約6の繰返し単位,重量平均分子量:約330
・ユニオール TG-1000,日油株式会社製
ポリプロピレングリコールのグリセリルエーテル,約16の繰返し単位,重量平均分子量:約1,000
ポリプロピレングリコールのジグリセリルエーテル,約9の繰返し単位,重量平均分子量:約700
・ユニオックスHC60,日油株式会社製
ポリオキシエチレン硬化ヒマシ油,重量平均分子量:約3,570
・ワセリン,コグニスジャパン株式会社製
石油に由来する炭化水素、半固形
なお、水溶解度は、上述の方法に従って測定したが、100gの脱塩水に、20.0gを添加し、24時間後に溶解した試料は、「20g<」と評価し、そして100gの脱塩水に、0.05gは溶解したが、1.00gは溶解しなかった試料は、0.05~1.00gと評価した。
また、融点に関し、「<45」は、融点が45℃未満であることを意味する。
上述の手順に従って、リウェット率と、吸収体移行速度とを測定した。結果を、下記表2に示す。
各血液改質剤を含むトップシートの上に、穴の開いたアクリル板(200mm×100mm,125g,中央に、40mm×10mmの穴が開いている)を置き、上記穴から、37±1℃のウマEDTA血(ウマの血液に、凝結防止のため、エチレンジアミン四酢酸(以下、「EDTA」と称する)が添加されたもの)3.0gを、ピペットを用いて滴下(1回目)し、1分後、37±1℃のウマEDTA血3.0gを、アクリル板の穴から、ピペットで再度滴下した(2回目)。
リウェット率(質量%)
=100×[FW1(g)-FW0(g)]/6.0(g)
リウェット率と、吸収体移行速度の結果を、以下の表2に示す。
◎:血液の赤さがほとんど残っておらず、血液が存在した場所と、存在していない場所の区別がつかない
○:血液の赤さが若干残っているが、血液の存在した場所と、存在していない場所の区別がつきいにくい
△:血液の赤さが若干残っており、血液が存在した場所が分かる
×:血液の赤さがそのまま残っている
結果を、併せて下記表2に示す。
なお、例2は、生理用ナプキンが所定の中高部を有しない例ではあるが、No.2-1~No.2-32の生理用ナプキンは、パナセート810sを含むNo.2-7と同等の結果が得られていることから、No.2-1~No.2-32の生理用ナプキンで用いられた血液改質剤を、例1で製造された吸収性物品No.1-1に塗工した場合には、吸収性物品No.1-2と同等の結果が得られるものと考えられる。
動物の各種血液に関して、上述の手順に従って、リウェット率を評価した。実験に用いられた血液は、以下の通りである。
[動物種]
(1)ヒト
(2)ウマ
(3)ヒツジ
・脱繊維血:血液を採取後、ガラスビーズと共に、三角フラスコ内で約5分間撹拌したもの
・EDTA血:静脈血65mLに、12%EDTA・2K生理食塩液0.5mLを添加したもの
血清又は血漿:それぞれ、脱繊維血又はEDTA血を、室温下で、約1900Gで10分間遠心分離した後の上清
血球:血液から血清を除去し、残差をリン酸緩衝生理食塩液(PBS)で2回洗浄し、次いで除去した血清分のリン酸緩衝生理食塩液を加えたもの
結果を、下記表3に示す。
[血液保持性の評価]
血液改質剤を含むトップシートと、血液改質剤を含まないトップシートとにおける血液保持性を評価した。
(1)エアスルー不織布(ポリエステル及びポリエチレンテレフタレートから成る複合繊維、坪量:35g/m2)から形成されたトップシートの肌当接面に、トリC2L油脂肪酸グリセリドを、コントロールシームHMAガンを用いて微粒化し、坪量がおおよそ5g/m2となるように塗布する。また、比較のため、トリC2L油脂肪酸グリセリドを塗布していないものも準備する。次いで、トリC2L油脂肪酸グリセリドが塗布されているトップシートと、塗布されていないトップシートとの両方を、0.2gの大きさにカットし、セルストレイナー+トップシートの質量:a(g)を正確に測定する。
(3)セルストレイナーを、遠心管にセットし、スピンダウンして、余剰のウマEDTA血を取り除く。
(4)セルストレイナー+ウマEDTA血を含むトップシートの重量:b(g)を測定する。
(5)下式に従って、トップシート1g当たりの当初吸収量(g)を算出する。
当初吸収量(g)=[b(g)-a(g)]/0.2(g)
(6)セルストレイナーを、遠心管に再セットし、室温下、約1200Gで1分間遠心分離する。
(8)下式に従って、トップシート1g当たりの試験後吸収量(g)を算出する。
試験後吸収量(g)=[c(g)-a(g)]/0.2(g)
(9)下式に従って血液保持率(質量%)を算出した。
血液保持率(質量%)
=100×試験後吸収量(g)/当初吸収量(g)
なお、測定は3回行い、その平均値を採用した。
結果を、下記表4に示す。
[血液改質剤を含む血液の粘性]
血液改質剤を含む血液の粘性を、Rheometric Expansion System ARES(Rheometric Scientific,Inc)を用いて測定した。ウマ脱繊維血に、パナセート810sを2質量%添加し、軽く撹拌して試料を形成し、直径50mmのパラレルプレートに試料を載せ、ギャップを100μmとし、37±0.5℃で粘度を測定した。パラレルプレートゆえ、試料に均一なせん断速度はかかっていないが、機器に表示された平均せん断速度は、10s-1であった。
血液は、血球等の成分を含み、チキソトロピーの性質を有することが知られているが、本開示の血液改質剤は、低粘度域で、血液の粘度を下げることができると考えられる。血液の粘度を下げることにより、吸収した経血を、トップシートから吸収体に速やかに移行させることができると考えられる。
[血液改質剤を含む血液の顕微鏡写真]
健常ボランティアの経血を食品保護用ラップフィルム上に採取し、その一部に、10倍の質量のリン酸緩衝生理食塩水中に分散されたパナセート810sを、パナセート810sの濃度が1質量%となるように添加した。経血を、スライドグラスに適下し、カバーグラスをかけ、光学顕微鏡にて、赤血球の状態を観察した。血液改質剤を含まない経血の顕微鏡写真を図8(a)に、そしてパナセート810sを含む経血の顕微鏡写真を図8(b)に示す。
[血液改質剤を含む血液の表面張力]
血液改質剤を含む血液の表面張力を、協和界面科学社製接触角計 Drop Master500を用い、ペンダントドロップ法にて測定した。表面張力は、ヒツジ脱繊維血に、所定の量の血液改質剤を添加し、十分振とうした後に測定した。
測定は、機器が自動で行うが、表面張力γは、以下の式により求められる(図9を参照)。
g:重力定数
1/H:ds/deから求められる補正項
ρ:密度
de:最大直径
ds:滴下端よりdeだけ上がった位置での径
測定には、京都電子工業株式会社のDA-505を用いた。
結果を、表5に示す。
血液の表面張力を下げることにより、吸収した血液をトップシートの繊維間に保持せず、速やかに吸収体に移行させることができると考えられる。
[態様1]
液透過性のトップシートと、液不透過性のバックシートと、上記液透過性のトップシート及び液不透過性のバックシートの間の吸収体を含む吸収性物品であって、
上記吸収性物品が、排泄口当接域において上記吸収性物品の厚さ方向に突出する中高部を有し、
上記中高部が、上記トップシートの一部と、上記トップシート及び吸収体の間に配置されているクッション部とを含み、
上記中高部が、中央部と、当該中央部を囲む外周部とを有し、そして
上記外周部におけるクッション部の密度が、上記中央部におけるクッション部の密度よりも高いことを特徴とする、
上記吸収性物品。
上記クッション部の外縁近傍に、少なくとも上記トップシート及び吸収体を圧搾することにより形成された圧搾部を有する、態様1に記載の吸収性物品。
[態様3]
上記クッション部が、複数の繊維を含み、上記複数の繊維の交点が熱融着されている、態様1又は2に記載の吸収性物品。
上記クッション部の最大厚さが、3~30mmである、態様1~3のいずれか1つに記載の吸収性物品。
[態様5]
上記クッション部が、ウマEDTA血2gを吸収させた後に、ウマEDTA血を吸収させる前と比較して、50%以上の最大厚さを保持する、態様1~4のいずれか1つに記載の吸収性物品。
上記吸収性物品が、上記中高部を内側に向けて湾曲する湾曲構造を有する、態様1~5のいずれか1つに記載の吸収性物品。
[態様7]
長手方向の両側縁部に、弾性部材を有する、態様1~6のいずれか1つに記載の吸収性物品。
上記トップシートが、肌当接面に、上記吸収性物品の長手方向に延びる、複数の畝部と、複数の溝部とを有する、態様1~7のいずれか1つに記載の吸収性物品。
[態様9]
上記中高部が、0.00~0.60のIOBと、45℃以下の融点と、25℃の水100gに対する、0.00~0.05gの水溶解度とを有する血液改質剤をさらに含む、態様1~8のいずれか1つに記載の吸収性物品。
上記血液改質剤が、次の(i)~(iii)、
(i)炭化水素、
(ii) (ii-1)炭化水素部分と、(ii-2)上記炭化水素部分のC-C単結合間に挿入された、カルボニル基(-CO-)及びオキシ基(-O-)から成る群から選択される、一又は複数の、同一又は異なる基とを有する化合物、及び
(iii) (iii-1)炭化水素部分と、(iii-2)上記炭化水素部分のC-C単結合間に挿入された、カルボニル基(-CO-)及びオキシ基(-O-)から成る群から選択される、一又は複数の、同一又は異なる基と、(iii-3)上記炭化水素部分の水素原子を置換する、カルボキシル基(-COOH)及びヒドロキシル基(-OH)から成る群から選択される、一又は複数の、同一又は異なる基とを有する化合物、
並びにそれらの任意の組み合わせから成る群から選択され、
ここで、(ii)又は(iii)の化合物において、オキシ基が2つ以上挿入されている場合には、各オキシ基は隣接していない、
態様9に記載の吸収性物品。
上記血液改質剤が、次の(i’)~(iii’)、
(i’)炭化水素、
(ii’) (ii’-1)炭化水素部分と、(ii’-2)上記炭化水素部分のC-C単結合間に挿入された、カルボニル結合(-CO-)、エステル結合(-COO-)、カーボネート結合(-OCOO-)、及びエーテル結合(-O-)から成る群から選択される、一又は複数の、同一又は異なる結合とを有する化合物、及び
(iii’) (iii’-1)炭化水素部分と、(iii’-2)上記炭化水素部分のC-C単結合間に挿入された、カルボニル結合(-CO-)、エステル結合(-COO-)、カーボネート結合(-OCOO-)、及びエーテル結合(-O-)から成る群から選択される、一又は複数の、同一又は異なる結合と、(iii’-3)上記炭化水素部分の水素原子を置換する、カルボキシル基(-COOH)及びヒドロキシル基(-OH)から成る群から選択される、一又は複数の、同一又は異なる基とを有する化合物、
並びにそれらの任意の組み合わせから成る群から選択され、
ここで、(ii’)又は(iii’)の化合物において、2以上の同一又は異なる結合が挿入されている場合には、各結合は隣接していない、
態様9又は10に記載の吸収性物品。
上記血液改質剤が、次の(A)~(F)、
(A) (A1)鎖状炭化水素部分と、上記鎖状炭化水素部分の水素原子を置換する2~4個のヒドロキシル基とを有する化合物と、(A2)鎖状炭化水素部分と、上記鎖状炭化水素部分の水素原子を置換する1個のカルボキシル基とを有する化合物とのエステル、
(B) (B1)鎖状炭化水素部分と、上記鎖状炭化水素部分の水素原子を置換する2~4個のヒドロキシル基とを有する化合物と、(B2)鎖状炭化水素部分と、上記鎖状炭化水素部分の水素原子を置換する1個のヒドロキシル基とを有する化合物とのエーテル、
(C) (C1)鎖状炭化水素部分と、上記鎖状炭化水素部分の水素原子を置換する、2~4個のカルボキシル基とを含むカルボン酸、ヒドロキシ酸、アルコキシ酸又はオキソ酸と、(C2)鎖状炭化水素部分と、上記鎖状炭化水素部分の水素原子を置換する1個のヒドロキシル基とを有する化合物とのエステル、
(D)鎖状炭化水素部分と、上記鎖状炭化水素部分のC-C単結合間に挿入された、エーテル結合(-O-)、カルボニル結合(-CO-)、エステル結合(-COO-)、及びカーボネート結合(-OCOO-)から成る群から選択されるいずれか1つの結合とを有する化合物、
(E)ポリオキシC2~C6アルキレングリコール、又はそのアルキルエステル若しくはアルキルエーテル、及び
(F)鎖状炭化水素、
並びにそれらの任意の組み合わせから成る群から選択される、態様9~11のいずれか1つに記載の吸収性物品。
上記血液改質剤が、(a1)鎖状炭化水素テトラオールと少なくとも1の脂肪酸とのエステル、(a2)鎖状炭化水素トリオールと少なくとも1の脂肪酸とのエステル、(a3)鎖状炭化水素ジオールと少なくとも1の脂肪酸とのエステル、(b1)鎖状炭化水素テトラオールと少なくとも1の脂肪族1価アルコールとのエーテル、(b2)鎖状炭化水素トリオールと少なくとも1の脂肪族1価アルコールとのエーテル、(b3)鎖状炭化水素ジオールと少なくとも1の脂肪族1価アルコールとのエーテル、(c1)4個のカルボキシル基を有する鎖状炭化水素テトラカルボン酸、ヒドロキシ酸、アルコキシ酸又はオキソ酸と、少なくとも1の脂肪族1価アルコールとのエステル、(c2)3個のカルボキシル基を有する鎖状炭化水素トリカルボン酸、ヒドロキシ酸、アルコキシ酸又はオキソ酸と、少なくとも1の脂肪族1価アルコールとのエステル、(c3)2個のカルボキシル基を有する鎖状炭化水素ジカルボン酸、ヒドロキシ酸、アルコキシ酸又はオキソ酸と、少なくとも1の脂肪族1価アルコールとのエステル、(d1)脂肪族1価アルコールと脂肪族1価アルコールとのエーテル、(d2)ジアルキルケトン、(d3)脂肪酸と脂肪族1価アルコールとのエステル、(d4)ジアルキルカーボネート、(e1)ポリオキシC2~C6アルキレングリコール、(e2)ポリオキシC2~C6アルキレングリコールと少なくとも1の脂肪酸とのエステル、(e3)ポリオキシC2~C6アルキレングリコールと少なくとも1の脂肪族1価アルコールとのエーテル、(e4)ポリオキシC2~C6アルキレングリコールと、鎖状炭化水素テトラカルボン酸、鎖状炭化水素トリカルボン酸、又は鎖状炭化水素ジカルボン酸とのエステル、(e5)ポリオキシC2~C6アルキレングリコールと、鎖状炭化水素テトラオール、鎖状炭化水素トリオール、又は鎖状炭化水素ジオールとのエーテル、及び(f1)鎖状アルカン、並びにそれらの任意の組み合わせから成る群から選択される、態様9~12のいずれか1つに記載の吸収性物品。
生理用ナプキン又はパンティーライナーである、態様1~13のいずれか1つに記載の吸収性物品。
[態様15]
態様2に記載の吸収性物品の製造方法であって、
上記吸収体、上記クッション部、及び上記トップシートを、その順番で積層するステップ、
上記クッション部の周辺に、少なくとも上記トップシート及び吸収体を圧搾することにより、圧搾部を形成するステップ、そして
上記吸収体に、上記バックシートを積層するステップ、
を含む、上記製造方法。
2 中高部
3 周囲部
4 圧搾部
5 トップシート
6 剥離部
7 クッション部
8 吸収体
9 バックシート
10 固定部
11 中央部
12 外周部
13 弾性部材
Claims (15)
- 液透過性のトップシートと、液不透過性のバックシートと、前記液透過性のトップシート及び液不透過性のバックシートの間の吸収体を含む吸収性物品であって、
前記吸収性物品が、排泄口当接域において前記吸収性物品の厚さ方向に突出する中高部を有し、
前記中高部が、前記トップシートの一部と、前記トップシート及び吸収体の間に配置されているクッション部とを含み、
前記中高部が、中央部と、当該中央部を囲む外周部とを有し、そして
前記外周部におけるクッション部の密度が、前記中央部におけるクッション部の密度よりも高いことを特徴とする、
前記吸収性物品。 - 前記クッション部の外縁近傍に、少なくとも前記トップシート及び吸収体を圧搾することにより形成された圧搾部を有する、請求項1に記載の吸収性物品。
- 前記クッション部が、複数の繊維を含み、前記複数の繊維の交点が熱融着されている、請求項1又は2に記載の吸収性物品。
- 前記クッション部の最大厚さが、3~30mmである、請求項1~3のいずれか一項に記載の吸収性物品。
- 前記クッション部が、ウマEDTA血2gを吸収させた後に、ウマEDTA血を吸収させる前と比較して、50%以上の最大厚さを保持する、請求項1~4のいずれか一項に記載の吸収性物品。
- 前記吸収性物品が、前記中高部を内側に向けて湾曲する湾曲構造を有する、請求項1~5のいずれか一項に記載の吸収性物品。
- 長手方向の両側縁部に、弾性部材を有する、請求項1~6のいずれか一項に記載の吸収性物品。
- 前記トップシートが、肌当接面に、前記吸収性物品の長手方向に延びる、複数の畝部と、複数の溝部とを有する、請求項1~7のいずれか一項に記載の吸収性物品。
- 前記中高部が、0.00~0.60のIOBと、45℃以下の融点と、25℃の水100gに対する、0.00~0.05gの水溶解度とを有する血液改質剤をさらに含む、請求項1~8のいずれか一項に記載の吸収性物品。
- 前記血液改質剤が、次の(i)~(iii)、
(i)炭化水素、
(ii) (ii-1)炭化水素部分と、(ii-2)前記炭化水素部分のC-C単結合間に挿入された、カルボニル基(-CO-)及びオキシ基(-O-)から成る群から選択される、一又は複数の、同一又は異なる基とを有する化合物、及び
(iii) (iii-1)炭化水素部分と、(iii-2)前記炭化水素部分のC-C単結合間に挿入された、カルボニル基(-CO-)及びオキシ基(-O-)から成る群から選択される、一又は複数の、同一又は異なる基と、(iii-3)前記炭化水素部分の水素原子を置換する、カルボキシル基(-COOH)及びヒドロキシル基(-OH)から成る群から選択される、一又は複数の、同一又は異なる基とを有する化合物、
並びにそれらの任意の組み合わせから成る群から選択され、
ここで、(ii)又は(iii)の化合物において、オキシ基が2つ以上挿入されている場合には、各オキシ基は隣接していない、
請求項9に記載の吸収性物品。 - 前記血液改質剤が、次の(i’)~(iii’)、
(i’)炭化水素、
(ii’) (ii’-1)炭化水素部分と、(ii’-2)前記炭化水素部分のC-C単結合間に挿入された、カルボニル結合(-CO-)、エステル結合(-COO-)、カーボネート結合(-OCOO-)、及びエーテル結合(-O-)から成る群から選択される、一又は複数の、同一又は異なる結合とを有する化合物、及び
(iii’) (iii’-1)炭化水素部分と、(iii’-2)前記炭化水素部分のC-C単結合間に挿入された、カルボニル結合(-CO-)、エステル結合(-COO-)、カーボネート結合(-OCOO-)、及びエーテル結合(-O-)から成る群から選択される、一又は複数の、同一又は異なる結合と、(iii’-3)前記炭化水素部分の水素原子を置換する、カルボキシル基(-COOH)及びヒドロキシル基(-OH)から成る群から選択される、一又は複数の、同一又は異なる基とを有する化合物、
並びにそれらの任意の組み合わせから成る群から選択され、
ここで、(ii’)又は(iii’)の化合物において、2以上の同一又は異なる結合が挿入されている場合には、各結合は隣接していない、
請求項9又は10に記載の吸収性物品。 - 前記血液改質剤が、次の(A)~(F)、
(A) (A1)鎖状炭化水素部分と、前記鎖状炭化水素部分の水素原子を置換する2~4個のヒドロキシル基とを有する化合物と、(A2)鎖状炭化水素部分と、前記鎖状炭化水素部分の水素原子を置換する1個のカルボキシル基とを有する化合物とのエステル、
(B) (B1)鎖状炭化水素部分と、前記鎖状炭化水素部分の水素原子を置換する2~4個のヒドロキシル基とを有する化合物と、(B2)鎖状炭化水素部分と、前記鎖状炭化水素部分の水素原子を置換する1個のヒドロキシル基とを有する化合物とのエーテル、
(C) (C1)鎖状炭化水素部分と、前記鎖状炭化水素部分の水素原子を置換する、2~4個のカルボキシル基とを含むカルボン酸、ヒドロキシ酸、アルコキシ酸又はオキソ酸と、(C2)鎖状炭化水素部分と、前記鎖状炭化水素部分の水素原子を置換する1個のヒドロキシル基とを有する化合物とのエステル、
(D)鎖状炭化水素部分と、前記鎖状炭化水素部分のC-C単結合間に挿入された、エーテル結合(-O-)、カルボニル結合(-CO-)、エステル結合(-COO-)、及びカーボネート結合(-OCOO-)から成る群から選択されるいずれか1つの結合とを有する化合物、
(E)ポリオキシC2~C6アルキレングリコール、又はそのアルキルエステル若しくはアルキルエーテル、及び
(F)鎖状炭化水素、
並びにそれらの任意の組み合わせから成る群から選択される、請求項9~11のいずれか一項に記載の吸収性物品。 - 前記血液改質剤が、(a1)鎖状炭化水素テトラオールと少なくとも1の脂肪酸とのエステル、(a2)鎖状炭化水素トリオールと少なくとも1の脂肪酸とのエステル、(a3)鎖状炭化水素ジオールと少なくとも1の脂肪酸とのエステル、(b1)鎖状炭化水素テトラオールと少なくとも1の脂肪族1価アルコールとのエーテル、(b2)鎖状炭化水素トリオールと少なくとも1の脂肪族1価アルコールとのエーテル、(b3)鎖状炭化水素ジオールと少なくとも1の脂肪族1価アルコールとのエーテル、(c1)4個のカルボキシル基を有する鎖状炭化水素テトラカルボン酸、ヒドロキシ酸、アルコキシ酸又はオキソ酸と、少なくとも1の脂肪族1価アルコールとのエステル、(c2)3個のカルボキシル基を有する鎖状炭化水素トリカルボン酸、ヒドロキシ酸、アルコキシ酸又はオキソ酸と、少なくとも1の脂肪族1価アルコールとのエステル、(c3)2個のカルボキシル基を有する鎖状炭化水素ジカルボン酸、ヒドロキシ酸、アルコキシ酸又はオキソ酸と、少なくとも1の脂肪族1価アルコールとのエステル、(d1)脂肪族1価アルコールと脂肪族1価アルコールとのエーテル、(d2)ジアルキルケトン、(d3)脂肪酸と脂肪族1価アルコールとのエステル、(d4)ジアルキルカーボネート、(e1)ポリオキシC2~C6アルキレングリコール、(e2)ポリオキシC2~C6アルキレングリコールと少なくとも1の脂肪酸とのエステル、(e3)ポリオキシC2~C6アルキレングリコールと少なくとも1の脂肪族1価アルコールとのエーテル、(e4)ポリオキシC2~C6アルキレングリコールと、鎖状炭化水素テトラカルボン酸、鎖状炭化水素トリカルボン酸、又は鎖状炭化水素ジカルボン酸とのエステル、(e5)ポリオキシC2~C6アルキレングリコールと、鎖状炭化水素テトラオール、鎖状炭化水素トリオール、又は鎖状炭化水素ジオールとのエーテル、及び(f1)鎖状アルカン、並びにそれらの任意の組み合わせから成る群から選択される、請求項9~12のいずれか一項に記載の吸収性物品。
- 生理用ナプキン又はパンティーライナーである、請求項1~13のいずれか一項に記載の吸収性物品。
- 請求項2に記載の吸収性物品の製造方法であって、
前記吸収体、前記クッション部、及び前記トップシートを、その順番で積層するステップ、
前記クッション部の外縁近傍に、少なくとも前記トップシート及び吸収体を圧搾することにより、圧搾部を形成するステップ、そして
前記吸収体に、前記バックシートを積層するステップ、
を含む、前記製造方法。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/368,521 US10278873B2 (en) | 2011-12-28 | 2012-12-19 | Absorbent article having a domed section and method of manufacturing same |
KR1020147020215A KR20140107532A (ko) | 2011-12-28 | 2012-12-19 | 흡수성 물품, 및 그 제조 방법 |
EP12863742.8A EP2799048B1 (en) | 2011-12-28 | 2012-12-19 | Absorbent article |
CN201280065107.3A CN104023682B (zh) | 2011-12-28 | 2012-12-19 | 吸收性物品及其制造方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011-289970 | 2011-12-28 | ||
JP2011289970 | 2011-12-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013099739A1 true WO2013099739A1 (ja) | 2013-07-04 |
Family
ID=48697228
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2012/082977 WO2013099739A1 (ja) | 2011-12-28 | 2012-12-19 | 吸収性物品、及びその製造方法 |
Country Status (8)
Country | Link |
---|---|
US (1) | US10278873B2 (ja) |
EP (1) | EP2799048B1 (ja) |
JP (1) | JP6057664B2 (ja) |
KR (1) | KR20140107532A (ja) |
CN (1) | CN104023682B (ja) |
AR (1) | AR089485A1 (ja) |
TW (1) | TWI572339B (ja) |
WO (1) | WO2013099739A1 (ja) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5957240B2 (ja) * | 2012-02-23 | 2016-07-27 | 大王製紙株式会社 | 吸収性物品の製造方法 |
US9744755B2 (en) * | 2013-04-01 | 2017-08-29 | 3M Innovative Properties Company | Method of making absorbent foam composites |
JP2015065980A (ja) * | 2013-09-26 | 2015-04-13 | ユニ・チャーム株式会社 | 吸収性物品 |
JP6333911B2 (ja) * | 2016-09-28 | 2018-05-30 | 花王株式会社 | 吸収性物品 |
US12016756B2 (en) | 2017-12-19 | 2024-06-25 | Lyv Life, Inc. | Ultrathin absorbent hygienic pads |
JP7150023B2 (ja) | 2017-12-21 | 2022-10-07 | エシティ・ハイジーン・アンド・ヘルス・アクチエボラグ | 吸収性物品 |
US11793683B2 (en) | 2017-12-21 | 2023-10-24 | Essity Hygiene And Health Aktiebolag | Absorbent article and method for manufacturing an absorbent article |
BR112020007555A2 (pt) | 2017-12-21 | 2020-09-24 | Essity Hygiene And Health Aktiebolag | artigo absorvente e método para fabricar um artigo absorvente |
MY196125A (en) | 2017-12-21 | 2023-03-15 | Essity Hygiene & Health Ab | Absorbent Article and Method for Manufacturing an Absorbent Article |
EP3727261B1 (en) | 2017-12-21 | 2024-03-06 | Essity Hygiene and Health Aktiebolag | Absorbent article with a sealing arrangement comprising welding spots and method for manufacturing the absorbent article |
EP3727259B1 (en) | 2017-12-21 | 2023-11-15 | Essity Hygiene and Health Aktiebolag | Absorbent article with a sealing arrangement having constant width |
US11147721B2 (en) * | 2017-12-21 | 2021-10-19 | Essity Hygiene And Health Aktiebolag | Absorbent article and method for manufacturing an absorbent article |
CN108852628A (zh) * | 2018-04-26 | 2018-11-23 | 广西舒雅护理用品有限公司 | 抗菌双芯药物卫生护垫 |
USD926974S1 (en) * | 2019-03-01 | 2021-08-03 | Lyv Life, Inc. | Ultrathin absorbent bladder liner with absorbent pod |
USD917044S1 (en) | 2019-03-01 | 2021-04-20 | Lyv Life, Inc. | Ultrathin absorbent asymmetrical bladder liner with channels |
USD917043S1 (en) | 2019-03-01 | 2021-04-20 | Lyv Life, Inc. | Ultrathin absorbent asymmetrical bladder liner |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06502104A (ja) * | 1991-07-23 | 1994-03-10 | ザ、プロクター、エンド、ギャンブル、カンパニー | 湾曲した吸収材製品 |
JP2002528174A (ja) | 1998-10-23 | 2002-09-03 | ザ、プロクター、エンド、ギャンブル、カンパニー | 選択的開閉自在開口を含むトップシートを有する吸収体 |
JP2008025079A (ja) | 2006-06-23 | 2008-02-07 | Uni Charm Corp | 不織布 |
JP2008025078A (ja) | 2006-06-23 | 2008-02-07 | Uni Charm Corp | 不織布 |
JP2008229032A (ja) | 2007-03-20 | 2008-10-02 | Kao Corp | 吸収性物品 |
JP2008229033A (ja) | 2007-03-20 | 2008-10-02 | Kao Corp | 吸収性物品 |
JP2010279568A (ja) * | 2009-06-04 | 2010-12-16 | Kao Corp | 吸収性物品 |
JP2011067484A (ja) * | 2009-09-28 | 2011-04-07 | Kao Corp | 吸収性物品 |
JP2011072650A (ja) * | 2009-09-30 | 2011-04-14 | Daio Paper Corp | 吸収性物品 |
JP2011104001A (ja) * | 2009-11-13 | 2011-06-02 | Kao Corp | 吸収性物品 |
JP2011226010A (ja) | 2010-04-16 | 2011-11-10 | Uni Charm Corp | 凹凸を有する不織布を簡易に製造する方法、及び不織布を簡易に加工する方法 |
JP2011226011A (ja) | 2010-04-16 | 2011-11-10 | Uni Charm Corp | 伸長性繊維と伸縮性繊維とを含む、凹凸を有する不織布、及び当該不織布を製造する方法 |
Family Cites Families (114)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3929135A (en) | 1974-12-20 | 1975-12-30 | Procter & Gamble | Absorptive structure having tapered capillaries |
JPS5717081A (en) | 1981-05-25 | 1982-01-28 | Noriko Ikegami | Electronic interpreter |
US4588630A (en) | 1984-06-13 | 1986-05-13 | Chicopee | Apertured fusible fabrics |
US4834735A (en) * | 1986-07-18 | 1989-05-30 | The Proctor & Gamble Company | High density absorbent members having lower density and lower basis weight acquisition zones |
JPH0775616B2 (ja) | 1987-07-30 | 1995-08-16 | 花王株式会社 | 衛生用品の表面材 |
DE3852732T2 (de) | 1987-07-30 | 1995-05-24 | Kao Corp | Sanitärartikel. |
US4759754A (en) | 1987-08-26 | 1988-07-26 | Personal Products Company | Sanitary napkin |
JPH082364B2 (ja) | 1987-12-16 | 1996-01-17 | 花王株式会社 | 衛生用品の表面材 |
JPH0720856B2 (ja) | 1988-12-01 | 1995-03-08 | 株式会社大塚製薬工場 | 皮膚の殺菌・清拭用組成物 |
JP2728921B2 (ja) | 1989-03-01 | 1998-03-18 | 花王株式会社 | 凹凸を有する不織布の製造方法 |
US5817079A (en) * | 1989-04-04 | 1998-10-06 | Mcneil-Ppc, Inc. | Selective placement of absorbent product materials in sanitary napkins and the like |
US5334176A (en) * | 1991-07-23 | 1994-08-02 | The Procter & Gamble Company | Absorbent core for use in catamenial products |
MA22660A1 (fr) | 1991-10-01 | 1993-04-01 | Procter & Gamble | Article absorbant comportant des rabats et des zones d'extensibilite differentielle . |
JP3091283B2 (ja) | 1991-12-09 | 2000-09-25 | 花王株式会社 | 生理用ナプキン |
JPH065614A (ja) | 1992-06-17 | 1994-01-14 | Murata Mfg Co Ltd | 熱処理装置 |
EP0699063A1 (en) | 1993-05-21 | 1996-03-06 | The Procter & Gamble Company | Absorbent article having anti-wicking crimp seal |
JPH0784697A (ja) | 1993-09-10 | 1995-03-31 | Canon Inc | 情報処理装置 |
US5614283A (en) | 1994-12-22 | 1997-03-25 | Tredegar Industries | Absorbent composite with three-dimensional film surface for use in absorbent disposable products |
JP2974934B2 (ja) | 1995-06-02 | 1999-11-10 | ザ、プロクター、エンド、ギャンブル、カンパニー | 生理用ナプキン |
US5650214A (en) | 1996-05-31 | 1997-07-22 | The Procter & Gamble Company | Web materials exhibiting elastic-like behavior and soft, cloth-like texture |
US5891126A (en) | 1996-08-30 | 1999-04-06 | The Procter & Gamble Company | Absorbent interlabial device treated with a polysiloxane emollient |
US6060636A (en) * | 1996-09-04 | 2000-05-09 | Kimberly-Clark Worldwide, Inc. | Treatment of materials to improve handling of viscoelastic fluids |
JPH1095810A (ja) | 1996-09-24 | 1998-04-14 | Oji Paper Co Ltd | 高吸水性樹脂及びその製造方法 |
SE509535C2 (sv) * | 1997-06-24 | 1999-02-08 | Moelnlycke Ab | Absorberande alster med förbättrad läckagesäkerhet |
ZA985679B (en) | 1997-06-30 | 1999-01-26 | Procter & Gamble | Absorbent article with multi-layered extensible wings |
WO1999029274A1 (en) | 1997-12-05 | 1999-06-17 | The Procter & Gamble Company | Compound sanitary napkin having flaps and zone of extensibility |
US6673982B1 (en) * | 1998-10-02 | 2004-01-06 | Kimberly-Clark Worldwide, Inc. | Absorbent article with center fill performance |
US6350711B1 (en) * | 1998-10-30 | 2002-02-26 | Kimberly-Clark Worldwide, Inc. | Absorbent article with fluid treatment agent |
US6673418B1 (en) * | 1998-12-23 | 2004-01-06 | Mcneil-Ppc, Inc. | Absorbent product having a non-woven fabric cover with a three-dimensional profile region |
US6730819B1 (en) | 1999-03-05 | 2004-05-04 | The Procter & Gamble Company | Articles comprising oxidizing and hemolytic agents |
EP1034804A1 (en) | 1999-03-05 | 2000-09-13 | The Procter & Gamble Company | Articles comprising an oxidising agent and a hemolytic agent |
US6153209A (en) | 1999-09-28 | 2000-11-28 | The Procter & Gamble Company | Article having a transferable breathable skin care composition thereon |
JP3748743B2 (ja) | 1999-10-04 | 2006-02-22 | ユニ・チャーム株式会社 | 吸収性物品およびその製造方法 |
JP3611761B2 (ja) | 1999-11-02 | 2005-01-19 | 花王株式会社 | 吸収性物品 |
US20010044614A1 (en) | 1999-12-23 | 2001-11-22 | Damay Emmanuelle Cecile | Reducing agents for feminine care products |
JP3701208B2 (ja) | 2000-03-13 | 2005-09-28 | ユニ・チャーム株式会社 | 開孔シートとこの開孔シートを使用した吸収性物品および前記開孔シートの製造方法。 |
JP3820096B2 (ja) | 2000-10-19 | 2006-09-13 | ユニ・チャーム株式会社 | 体液吸収性のパネル |
EP1250940B1 (en) | 2001-04-17 | 2010-01-06 | The Procter & Gamble Company | An absorbent article comprising an agent able to convey a perception to the wearer |
JP3922895B2 (ja) * | 2001-06-29 | 2007-05-30 | ユニ・チャーム株式会社 | 生理用ナプキン |
JP3926587B2 (ja) | 2001-07-12 | 2007-06-06 | ユニ・チャーム株式会社 | 吸収性物品 |
JP4855606B2 (ja) | 2001-08-10 | 2012-01-18 | ユニ・チャーム株式会社 | 吸収性物品 |
SE519783C2 (sv) | 2001-08-31 | 2003-04-08 | Sca Hygiene Prod Ab | Absorberande alster innefattande öppningar i absorptionskroppen |
US20030082219A1 (en) | 2001-10-01 | 2003-05-01 | The Procter & Gamble Company | Skin care compositions comprising low concentrations of skin treatment agents |
SG103382A1 (en) | 2002-01-11 | 2004-04-29 | Uni Charm Corp | Colored absorbent article |
JP4693847B2 (ja) | 2002-03-26 | 2011-06-01 | ユニ・チャーム株式会社 | 吸収性物品およびその製造方法 |
JP4278963B2 (ja) | 2002-03-26 | 2009-06-17 | ユニ・チャーム株式会社 | 吸収性物品 |
DE60231704D1 (de) | 2002-06-12 | 2009-05-07 | Sca Hygiene Prod Ab | Absorbierender Artikel mit einer Hautpflegezusammensetzung |
JP3949020B2 (ja) | 2002-07-19 | 2007-07-25 | 花王株式会社 | 吸収性物品 |
US9035123B2 (en) | 2002-10-01 | 2015-05-19 | The Procter & Gamble Company | Absorbent article having a lotioned topsheet |
US8030535B2 (en) | 2002-12-18 | 2011-10-04 | The Procter & Gamble Company | Sanitary napkin for clean body benefit |
JP2005095759A (ja) | 2003-09-24 | 2005-04-14 | San-Dia Polymer Ltd | 吸収剤とこれを用いてなる吸収性物品 |
US20050096614A1 (en) | 2003-10-29 | 2005-05-05 | Perez Roberto C. | Cover layer for an absorbent article |
JP4476102B2 (ja) | 2003-12-11 | 2010-06-09 | 花王株式会社 | 吸収性物品の表面シート |
CA2706867C (en) | 2004-06-21 | 2011-04-12 | The Procter & Gamble Company | Absorbent article with lotion-containing topsheet |
US8324446B2 (en) * | 2004-06-30 | 2012-12-04 | Kimberly-Clark Worldwide, Inc. | Unitary absorbent core with binding agents |
JP4459013B2 (ja) | 2004-10-20 | 2010-04-28 | 花王株式会社 | 吸収性物品 |
US8211078B2 (en) | 2005-02-17 | 2012-07-03 | The Procter And Gamble Company | Sanitary napkins capable of taking complex three-dimensional shape in use |
JP4514630B2 (ja) | 2005-03-16 | 2010-07-28 | 花王株式会社 | 吸収性物品の表面シート |
JP4523866B2 (ja) | 2005-03-31 | 2010-08-11 | ユニ・チャーム株式会社 | 吸収性物品 |
JP2008541943A (ja) | 2005-06-02 | 2008-11-27 | ザ プロクター アンド ギャンブル カンパニー | 横方向強化要素を有する吸収性物品 |
JP4792249B2 (ja) | 2005-07-11 | 2011-10-12 | ユニ・チャーム株式会社 | 体液吸収性物品 |
JPWO2007039974A1 (ja) * | 2005-10-03 | 2009-04-16 | 大正製薬株式会社 | 乳剤性ローション剤 |
EP1993498A1 (en) | 2006-03-14 | 2008-11-26 | The Procter and Gamble Company | Absorbent articles with lotions |
JP5154048B2 (ja) | 2006-06-23 | 2013-02-27 | ユニ・チャーム株式会社 | 不織布 |
JP5123497B2 (ja) | 2006-06-23 | 2013-01-23 | ユニ・チャーム株式会社 | 不織布、不織布製造方法及び不織布製造装置 |
JP5328089B2 (ja) | 2006-06-23 | 2013-10-30 | ユニ・チャーム株式会社 | 多層不織布及び多層不織布の製造方法 |
JP5123512B2 (ja) | 2006-06-23 | 2013-01-23 | ユニ・チャーム株式会社 | 不織布 |
JP5123513B2 (ja) | 2006-06-23 | 2013-01-23 | ユニ・チャーム株式会社 | 吸収体 |
CN101542032B (zh) * | 2006-06-23 | 2011-08-24 | 尤妮佳股份有限公司 | 无纺布 |
WO2007148799A1 (ja) | 2006-06-23 | 2007-12-27 | Uni-Charm Corporation | 吸収性物品 |
JP5069891B2 (ja) | 2006-06-23 | 2012-11-07 | ユニ・チャーム株式会社 | 不織布 |
JP5328088B2 (ja) | 2006-06-23 | 2013-10-30 | ユニ・チャーム株式会社 | 不織布 |
JP5069890B2 (ja) | 2006-06-23 | 2012-11-07 | ユニ・チャーム株式会社 | 不織布 |
JP4986673B2 (ja) | 2007-03-27 | 2012-07-25 | 花王株式会社 | 吸収性物品 |
EP2036521A4 (en) | 2006-07-05 | 2012-06-20 | Kao Corp | ABSORBENT ARTICLE |
JP5021380B2 (ja) | 2006-07-05 | 2012-09-05 | 花王株式会社 | 吸収性物品 |
JP4749288B2 (ja) | 2006-09-06 | 2011-08-17 | 花王株式会社 | 吸収性物品 |
US8998871B2 (en) * | 2006-11-22 | 2015-04-07 | Uni-Charm Corporation | Absorbent article with compressed channel portions |
JP4939196B2 (ja) | 2006-12-12 | 2012-05-23 | ユニ・チャーム株式会社 | 不織布、不織布の製造方法及び吸収性物品 |
ATE528425T1 (de) | 2006-12-05 | 2011-10-15 | Uni Charm Corp | Vliesstoff, verfahren zur herstellung von vliesstoff sowie saugkörper |
JP4939192B2 (ja) | 2006-12-05 | 2012-05-23 | ユニ・チャーム株式会社 | 不織布、不織布の製造方法及び吸収性物品 |
MY148995A (en) | 2006-12-13 | 2013-06-28 | Uni Charm Corp | Absorbent article |
AR065378A1 (es) | 2007-02-16 | 2009-06-03 | Procter & Gamble | Articulo absorbente con locion que comprende un material de polipropilenglicol |
JP4879074B2 (ja) | 2007-04-17 | 2012-02-15 | ユニ・チャーム株式会社 | 不織布製造方法 |
JP5114087B2 (ja) | 2007-04-17 | 2013-01-09 | ユニ・チャーム株式会社 | 不織布、及び、吸収性物品 |
WO2008133067A1 (ja) | 2007-04-17 | 2008-11-06 | Uni-Charm Corporation | 不織布、不織布製造方法、及び、吸収性物品 |
EP1992366B1 (en) | 2007-05-15 | 2011-07-06 | The Procter & Gamble Company | Use of a lotion composition on an absorbent article for reducing adherence of feces or menses to the skin |
JP5161491B2 (ja) | 2007-05-30 | 2013-03-13 | ユニ・チャーム株式会社 | 吸収性物品 |
JP5568210B2 (ja) | 2007-06-13 | 2014-08-06 | ユニ・チャーム株式会社 | 不織布シートの製造方法 |
JP5497987B2 (ja) | 2007-06-22 | 2014-05-21 | ユニ・チャーム株式会社 | 不織布およびその製造方法 |
JP2009005767A (ja) | 2007-06-26 | 2009-01-15 | Kao Corp | 吸収性物品 |
JP4652387B2 (ja) | 2007-10-03 | 2011-03-16 | 王子製紙株式会社 | 折り返し部を有する吸収体製品 |
JP5254363B2 (ja) | 2008-02-15 | 2013-08-07 | ザ プロクター アンド ギャンブル カンパニー | ポリプロピレングリコール材料を含むローションを備える吸収性物品 |
JP2009201878A (ja) | 2008-02-29 | 2009-09-10 | Uni Charm Corp | 吸収性物品 |
JP5258380B2 (ja) * | 2008-05-15 | 2013-08-07 | ユニ・チャーム株式会社 | 吸収性物品 |
JP5173616B2 (ja) | 2008-06-10 | 2013-04-03 | 花王株式会社 | 吸収性物品 |
JP5371361B2 (ja) | 2008-10-10 | 2013-12-18 | ユニ・チャーム株式会社 | 吸収性物品及び吸収性物品の製造方法 |
JP5455363B2 (ja) | 2008-12-25 | 2014-03-26 | ユニ・チャーム株式会社 | 薄型吸収性物品 |
JP5520124B2 (ja) | 2009-05-14 | 2014-06-11 | ユニ・チャーム株式会社 | 透液性繊維不織布 |
RU2555615C2 (ru) | 2009-05-20 | 2015-07-10 | Као Корпорейшн | Абсорбирующее тело и абсорбирующее изделие |
JP5451179B2 (ja) * | 2009-05-20 | 2014-03-26 | 花王株式会社 | 吸収体および吸収性物品 |
JP5590834B2 (ja) | 2009-08-11 | 2014-09-17 | ユニ・チャーム株式会社 | 不織布およびその製造方法 |
JP5623052B2 (ja) | 2009-09-29 | 2014-11-12 | ユニ・チャーム株式会社 | 不織布の製造方法 |
JP5421720B2 (ja) | 2009-10-09 | 2014-02-19 | ユニ・チャーム株式会社 | 不織布 |
JP5466489B2 (ja) | 2009-11-16 | 2014-04-09 | 花王株式会社 | 吸収性物品 |
JP2011131044A (ja) * | 2009-11-24 | 2011-07-07 | Kao Corp | 吸収性物品 |
JP5551926B2 (ja) | 2009-12-09 | 2014-07-16 | 花王株式会社 | 吸収性物品 |
JP5749907B2 (ja) | 2010-08-31 | 2015-07-15 | ユニ・チャーム株式会社 | 吸収性物品及び生理用ナプキン |
US8921640B2 (en) * | 2010-10-08 | 2014-12-30 | The Procter & Gamble Company | Absorbent article with philic anhydrous lotion |
TWI448277B (zh) | 2011-03-31 | 2014-08-11 | Uni Charm Corp | Absorbent items |
JP6092508B2 (ja) * | 2011-09-30 | 2017-03-08 | ユニ・チャーム株式会社 | 吸収性物品 |
JP5726121B2 (ja) * | 2012-03-30 | 2015-05-27 | ユニ・チャーム株式会社 | 吸収性物品 |
US9283127B2 (en) * | 2012-03-30 | 2016-03-15 | Kimberly-Clark Worldwide, Inc. | Absorbent articles with decolorizing structures |
JP6502104B2 (ja) | 2015-01-29 | 2019-04-17 | 帝人株式会社 | 伸縮性電線 |
-
2012
- 2012-10-25 JP JP2012235681A patent/JP6057664B2/ja not_active Expired - Fee Related
- 2012-12-19 WO PCT/JP2012/082977 patent/WO2013099739A1/ja active Application Filing
- 2012-12-19 EP EP12863742.8A patent/EP2799048B1/en not_active Not-in-force
- 2012-12-19 CN CN201280065107.3A patent/CN104023682B/zh not_active Expired - Fee Related
- 2012-12-19 KR KR1020147020215A patent/KR20140107532A/ko not_active Application Discontinuation
- 2012-12-19 US US14/368,521 patent/US10278873B2/en not_active Expired - Fee Related
- 2012-12-27 TW TW101150548A patent/TWI572339B/zh not_active IP Right Cessation
- 2012-12-27 AR ARP120105005A patent/AR089485A1/es not_active Application Discontinuation
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06502104A (ja) * | 1991-07-23 | 1994-03-10 | ザ、プロクター、エンド、ギャンブル、カンパニー | 湾曲した吸収材製品 |
JP2002528174A (ja) | 1998-10-23 | 2002-09-03 | ザ、プロクター、エンド、ギャンブル、カンパニー | 選択的開閉自在開口を含むトップシートを有する吸収体 |
JP2008025079A (ja) | 2006-06-23 | 2008-02-07 | Uni Charm Corp | 不織布 |
JP2008025078A (ja) | 2006-06-23 | 2008-02-07 | Uni Charm Corp | 不織布 |
JP2008229032A (ja) | 2007-03-20 | 2008-10-02 | Kao Corp | 吸収性物品 |
JP2008229033A (ja) | 2007-03-20 | 2008-10-02 | Kao Corp | 吸収性物品 |
JP2010279568A (ja) * | 2009-06-04 | 2010-12-16 | Kao Corp | 吸収性物品 |
JP2011067484A (ja) * | 2009-09-28 | 2011-04-07 | Kao Corp | 吸収性物品 |
JP2011072650A (ja) * | 2009-09-30 | 2011-04-14 | Daio Paper Corp | 吸収性物品 |
JP2011104001A (ja) * | 2009-11-13 | 2011-06-02 | Kao Corp | 吸収性物品 |
JP2011226010A (ja) | 2010-04-16 | 2011-11-10 | Uni Charm Corp | 凹凸を有する不織布を簡易に製造する方法、及び不織布を簡易に加工する方法 |
JP2011226011A (ja) | 2010-04-16 | 2011-11-10 | Uni Charm Corp | 伸長性繊維と伸縮性繊維とを含む、凹凸を有する不織布、及び当該不織布を製造する方法 |
Non-Patent Citations (1)
Title |
---|
FUJITA A.: "Organic compound predictions and organic paradigms", KAGAKU NO RYOIKI, vol. 11, no. 10, 1957, pages 719 - 725 |
Also Published As
Publication number | Publication date |
---|---|
US20150032073A1 (en) | 2015-01-29 |
TWI572339B (zh) | 2017-03-01 |
JP6057664B2 (ja) | 2017-01-11 |
CN104023682B (zh) | 2015-11-25 |
EP2799048A4 (en) | 2015-08-26 |
AR089485A1 (es) | 2014-08-27 |
EP2799048B1 (en) | 2018-04-25 |
JP2013150779A (ja) | 2013-08-08 |
TW201340951A (zh) | 2013-10-16 |
US10278873B2 (en) | 2019-05-07 |
KR20140107532A (ko) | 2014-09-04 |
CN104023682A (zh) | 2014-09-03 |
EP2799048A1 (en) | 2014-11-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6057664B2 (ja) | 吸収性物品、及びその製造方法 | |
JP5122007B1 (ja) | 吸収性物品 | |
JP5925015B2 (ja) | 吸収性物品 | |
JP5726121B2 (ja) | 吸収性物品 | |
JP5726120B2 (ja) | 吸収性物品 | |
JP5717686B2 (ja) | 吸収性物品 | |
JP5745487B2 (ja) | 吸収性物品 | |
JP5847055B2 (ja) | 吸収性物品 | |
JP6092508B2 (ja) | 吸収性物品 | |
JP5709788B2 (ja) | 吸収性物品 | |
JP2013208419A (ja) | 吸収性物品 | |
JP5769655B2 (ja) | 吸収性物品 | |
JP5762346B2 (ja) | 吸収性物品 | |
JP5709789B2 (ja) | 吸収性物品 | |
WO2013129326A1 (ja) | 吸収性物品 | |
JP2013208410A (ja) | 吸収性物品 | |
JP2017109125A (ja) | 吸収性物品 | |
WO2013129325A1 (ja) | 吸収性物品 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12863742 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012863742 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14368521 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20147020215 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: IDP00201404549 Country of ref document: ID |